The	O
Sp1	B-protein
transcription	I-protein
factor	I-protein
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
specifically	O
in	O
myeloid	O
cells	O
in	O
vivo	O
and	O
is	O
essential	O
for	O
myeloid-specific	B-DNA
promoter	I-DNA
activity	O
.	O

The	O
myeloid	B-protein
integrin	I-protein
CD11b	I-protein
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	B-cell_type
macrophages	I-cell_type
,	O
monocytes	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

Lineage-specific	O
expression	O
is	O
controlled	O
at	O
the	O
level	O
of	O
mRNA	O
transcription	O
.	O

Recent	O
isolation	O
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5'-flanking	B-DNA
DNA	I-DNA
are	O
sufficient	O
to	O
direct	O
myeloid-specific	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
.	O

To	O
characterize	O
regulatory	O
sequences	O
important	O
for	O
promoter	O
activity	O
,	O
we	O
performed	O
linker	O
scanning	O
analysis	O
of	O
the	O
92-bp	B-DNA
CD11b	I-DNA
promoter	I-DNA
and	O
demonstrate	O
that	O
a	O
sequence	O
at	O
bp	O
-60	O
is	O
essential	O
for	O
CD11b	B-DNA
promoter	I-DNA
activity	O
.	O

We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vivo	O
the	O
Sp1	B-DNA
site	I-DNA
is	O
bound	O
only	O
in	O
myeloid	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
not	O
in	O
cervical	B-cell_line
carcinoma	I-cell_line
(	I-cell_line
HeLa	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
the	O
macrophage	O
transcription	B-protein
factor	I-protein
PU.1	O
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	B-DNA
site	I-DNA
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	B-protein
factor	I-protein
(	O
PU.1	B-protein
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B-protein
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	B-cell_line
.	O

THz	NULL
JourNat	NULL
or	NULL
CHEMISTRY	NULL
©1993	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

268	NULL
,	NULL
No	NULL
.	NULL

11	NULL
,	NULL
Issue	NULL
of	NULL
April	NULL
15	NULL
,	NULL
pp	NULL
.	NULL

8230-8239	NULL
,	NULL
1993	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

The	NULL
Spl	NULL
Transcription	NULL
Factor	NULL
Binds	NULL
the	NULL
CD11b	NULL
Promoter	NULL
Specifically	NULL
in	NULL
Myeloid	NULL
Cells	NULL
in	NULL
Vivo	NULL
and	NULL
Is	NULL
Essential	NULL
for	NULL
Myeloid-specific	NULL
Promoter	NULL
Activity*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
June	NULL
19	NULL
,	NULL
1992	NULL
)	NULL
Hui-Min	NULL
Chent§	NULL
,	NULL
Heike	NULL
L.	NULL
Pahl	NULL
#	NULL
§	NULL
(	NULL
||	NULL
,	NULL
Renate	NULL
J.	NULL
Scheibet	NULL
,	NULL
Dong-Er	NULL
Zhang	NULL
}	NULL
,	NULL
and	NULL
Daniel	NULL
G.	NULL
Tenent**	NULL
From	NULL
the	NULL
{	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Hematology/Oncology	NULL
Division	NULL
,	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
and	NULL
the	NULL
[	NULL
Department	NULL
of	NULL
Genetics	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02215	NULL
The	NULL
myeloid	NULL
integrin	NULL
CD11b	NULL
is	NULL
expressed	NULL
selectively	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
mature	NULL
macrophages	NULL
,	NULL
monocytes	NULL
,	NULL
neutrophils	NULL
,	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Lineage-specific	NULL
expression	NULL
is	NULL
controlled	NULL
at	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
tran-scription	NULL
.	NULL

Recent	NULL
isolation	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
shows	NULL
that	NULL
92	NULL
base	NULL
pairs	NULL
(	NULL
bp	NULL
)	NULL
of	NULL
5'-flanking	NULL
DNA	NULL
are	NULL
sufficient	NULL
to	NULL
direct	NULL
myeloid-specific	NULL
expression	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
.	NULL

To	NULL
characterize	NULL
regulatory	NULL
sequences	NULL
important	NULL
for	NULL
promoter	NULL
activity	NULL
,	NULL
we	NULL
performed	NULL
linker	NULL
scanning	NULL
analysis	NULL
of	NULL
the	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
and	NULL
demonstrate	NULL
that	NULL
a	NULL
sequence	NULL
at	NULL
bp	NULL
-60	NULL
is	NULL
essential	NULL
for	NULL
CD11b	NULL
promoter	NULL
activity	NULL
.	NULL

We	NULL
show	NULL
that	NULL
this	NULL
sequence	NULL
binds	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
vivo	NULL
the	NULL
Spl	NULL
site	NULL
is	NULL
bound	NULL
only	NULL
in	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
cells	NULL
,	NULL
not	NULL
in	NULL
cervical	NULL
carcinoma	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
CD11b	NULL
promoter	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
close	NULL
to	NULL
the	NULL
Spl	NULL
site	NULL
.	NULL

We	NULL
propose	NULL
a	NULL
model	NULL
in	NULL
which	NULL
binding	NULL
of	NULL
a	NULL
myeloid-specific	NULL
factor	NULL
(	NULL
PU.1	NULL
)	NULL
allows	NULL
a	NULL
general	NULL
factor	NULL
(	NULL
Sp1	NULL
)	NULL
to	NULL
bind	NULL
in	NULL
a	NULL
tissue-specific	NULL
fashion	NULL
thereby	NULL
contributing	NULL
to	NULL
the	NULL
myeloid-specific	NULL
expression	NULL
of	NULL
CD11b	NULL
.	NULL

In	NULL
the	NULL
hematopoietic	NULL
system	NULL
,	NULL
pluripotential	NULL
stem	NULL
cells	NULL
develop	NULL
to	NULL
form	NULL
a	NULL
variety	NULL
of	NULL
mature	NULL
circulating	NULL
blood	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
factors	NULL
committing	NULL
pluripotential	NULL
progenitors	NULL
to	NULL
differentiation	NULL
along	NULL
a	NULL
specific	NULL
lineage	NULL
are	NULL
poorly	NULL
understood	NULL
.	NULL

Furthermore	NULL
,	NULL
only	NULL
some	NULL
factors	NULL
responsible	NULL
for	NULL
lineage-specific	NULL
gene	NULL
expression	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

In	NULL
the	NULL
erythroid	NULL
lineage	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
,	NULL
GATA-1	NULL
,	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
development	NULL
of	NULL
mature	NULL
,	NULL
circulating	NULL
red	NULL
blood	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
GATA-1	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
many	NULL
erythroid-specific	NULL
genes	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

GATA-1	NULL
is	NULL
an	NULL
example	NULL
of	NULL
a	NULL
``	NULL
master	NULL
transcription	NULL
factor	NULL
,	NULL
``	NULL
a	NULL
single	NULL
factor	NULL
sufficient	NULL
to	NULL
induce	NULL
lineage-specific	NULL
differentiation	NULL
and	NULL
gene	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
not	NULL
known	NULL
*This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
Grant	NULL
CA41456	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
(	NULL
to	NULL
D.	NULL
G.	NULL
T.	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
(	NULL
s	NULL
)	NULL
reported	NULL
in	NULL
this	NULL
paper	NULL
has	NULL
been	NULL
submitted	NULL
to	NULL
the	NULL
GenBank	NULL
``	NULL
``	NULL
/EMBL	NULL
Date	NULL
Bank	NULL
with	NULL
accession	NULL
number	NULL
(	NULL
s	NULL
)	NULL
M80772	NULL
.	NULL

§	NULL
The	NULL
first	NULL
two	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
study	NULL
and	NULL
are	NULL
listed	NULL
in	NULL
alphabetical	NULL
order	NULL
.	NULL

|	NULL
Present	NULL
address	NULL
:	NULL
Gen-Zentrum	NULL
Miinchen	NULL
,	NULL
Am	NULL
Klopferspitz	NULL
,	NULL
8033	NULL
Martinsried	NULL
,	NULL
Germany	NULL
.	NULL

**	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
,	NULL
Research	NULL
East	NULL
Rm	NULL
.	NULL

219B	NULL
,	NULL
330	NULL
Brookline	NULL
Ave.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02215	NULL
.	NULL

Tel	NULL
:	NULL
617-735-5561	NULL
;	NULL
Fax	NULL
:	NULL
617-735-3299.	NULL
whether	NULL
the	NULL
differentiation	NULL
of	NULL
every	NULL
lineage	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
master	NULL
transcription	NULL
factor	NULL
.	NULL

In	NULL
an	NULL
alternative	NULL
model	NULL
,	NULL
commonly	NULL
expressed	NULL
transcription	NULL
factors	NULL
could	NULL
form	NULL
unique	NULL
combinations	NULL
to	NULL
generate	NULL
lineage-specific	NULL
expression	NULL
of	NULL
target	NULL
genes	NULL
.	NULL

Since	NULL
very	NULL
little	NULL
is	NULL
known	NULL
about	NULL
factors	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
myeloid	NULL
(	NULL
monocytic	NULL
,	NULL
neutrophilic	NULL
)	NULL
genes	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
study	NULL
the	NULL
expression	NULL
of	NULL
CD11b	NULL
,	NULL
a	NULL
marker	NULL
of	NULL
the	NULL
myeloid	NULL
lineage	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
heterodimeric	NULL
surface	NULL
antigen	NULL
CD11b/CD18	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
integrin	NULL
family	NULL
of	NULL
cell	NULL
surface	NULL
receptors	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

While	NULL
CD18	NULL
,	NULL
the	NULL
8	NULL
subunit	NULL
of	NULL
the	NULL
heterodimer	NULL
,	NULL
is	NULL
expressed	NULL
in	NULL
all	NULL
leukocytes	NULL
(	NULL
9	NULL
)	NULL
,	NULL
expression	NULL
of	NULL
CD11b	NULL
,	NULL
the	NULL
«	NULL
subunit	NULL
,	NULL
is	NULL
restricted	NULL
to	NULL
mature	NULL
macrophages	NULL
,	NULL
monocytes	NULL
,	NULL
neutrophils	NULL
,	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
(	NULL
6	NULL
)	NULL
.	NULL

CD11b	NULL
is	NULL
not	NULL
expressed	NULL
on	NULL
immature	NULL
precursor	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
antigen	NULL
expression	NULL
increases	NULL
up	NULL
to	NULL
40-fold	NULL
during	NULL
myeloid	NULL
differentiation	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Using	NULL
run-on	NULL
transcription	NULL
assays	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
CD11b	NULL
expression	NULL
and	NULL
up-regulation	NULL
are	NULL
controlled	NULL
at	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
transcription	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
we	NULL
cloned	NULL
the	NULL
CD11b	NULL
promoter	NULL
and	NULL
have	NULL
shown	NULL
that	NULL
92	NULL
bp	NULL
!	NULL

immediately	NULL
5	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
are	NULL
sufficient	NULL
to	NULL
direct	NULL
reporter	NULL
gene	NULL
activity	NULL
specifically	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
transient	NULL
transfection	NULL
assays	NULL
using	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
,	NULL
the	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
directs	NULL
100-fold	NULL
more	NULL
luciferase	NULL
activity	NULL
in	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
than	NULL
in	NULL
non-myeloid	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
proto-onco-gene	NULL
and	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
CD11b	NULL
promoter	NULL
at	NULL
bp	NULL
-20	NULL
and	NULL
that	NULL
mutation	NULL
of	NULL
this	NULL
site	NULL
reduces	NULL
CD11b	NULL
promoter	NULL
activity	NULL
3-6-fold	NULL
in	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
non-myeloid	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PU.1	NULL
represents	NULL
a	NULL
major	NULL
determinant	NULL
of	NULL
the	NULL
myeloid-specific	NULL
expression	NULL
of	NULL
CD11b	NULL
.	NULL

However	NULL
,	NULL
after	NULL
mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
,	NULL
the	NULL
CD11b	NULL
promoter	NULL
still	NULL
directs	NULL
significant	NULL
levels	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
(	NULL
12	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
find	NULL
additional	NULL
regulatory	NULL
elements	NULL
,	NULL
we	NULL
performed	NULL
linker	NULL
scanning	NULL
analysis	NULL
of	NULL
the	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
sequences	NULL
around	NULL
bp	NULL
-60	NULL
are	NULL
essential	NULL
for	NULL
promoter	NULL
activity	NULL
and	NULL
bind	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
the	NULL
Spl	NULL
site	NULL
is	NULL
only	NULL
occupied	NULL
in	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
cells	NULL
,	NULL
not	NULL
in	NULL
non-myeloid	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
contributes	NULL
to	NULL
the	NULL
myeloid-specific	NULL
expression	NULL
of	NULL
CD11b	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Linker	NULL
Scanning	NULL
Analysis-A	NULL
10-bp	NULL
linker	NULL
,	NULL
containing	NULL
a	NULL
BamHI	NULL
restriction	NULL
site	NULL
(	NULL
sequence	NULL
5-GGATCCCAGA-3	NULL
'	NULL
)	NULL
was	NULL
substituted	NULL
for	NULL
'	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
TPA	NULL
,	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
;	NULL
RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
cpm	NULL
,	NULL
counts/minute	NULL
;	NULL
wt	NULL
,	NULL
wild	NULL
type	NULL
.	NULL

8230	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
the	NULL
wild	NULL
type	NULL
sequence	NULL
between	NULL
bp	NULL
-95	NULL
and	NULL
-85	NULL
(	NULL
-95/-85	NULL
)	NULL
,	NULL
bp	NULL
-85	NULL
and	NULL
-75	NULL
(	NULL
-85/-75	NULL
)	NULL
,	NULL
bp	NULL
-75	NULL
and	NULL
-65	NULL
(	NULL
-75/-65	NULL
)	NULL
,	NULL
bp	NULL
-65	NULL
and	NULL
-55	NULL
(	NULL
-65/-55	NULL
)	NULL
,	NULL
bp	NULL
-55	NULL
and	NULL
-45	NULL
(	NULL
-55/-45	NULL
)	NULL
,	NULL
bp	NULL
-45	NULL
and	NULL
-35	NULL
(	NULL
-45/-35	NULL
)	NULL
,	NULL
bp	NULL
-35	NULL
and	NULL
-25	NULL
(	NULL
-35/-25	NULL
)	NULL
,	NULL
bp	NULL
-25	NULL
and	NULL
-15	NULL
(	NULL
-25/-15	NULL
)	NULL
,	NULL
and	NULL
bp	NULL
-15	NULL
and	NULL
-5	NULL
(	NULL
-15/-5	NULL
)	NULL
of	NULL
the	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
by	NULL
oligonucleotide-directed	NULL
PCR	NULL
mutagenesis	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
the	NULL
-75/-45	NULL
mutant	NULL
,	NULL
bp	NULL
-75	NULL
to	NULL
-45	NULL
are	NULL
replaced	NULL
by	NULL
the	NULL
10-bp	NULL
linker	NULL
oligonucleotide	NULL
.	NULL

PCR	NULL
fragments	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
luciferase	NULL
vector	NULL
pXP2	NULL
(	NULL
14	NULL
)	NULL
and	NULL
resulting	NULL
constructs	NULL
sequenced	NULL
to	NULL
confirm	NULL
correct	NULL
placement	NULL
of	NULL
the	NULL
linker	NULL
oligonucleotide	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Transfections-U937	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electro-poration	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
at	NULL
960	NULL
microfarads	NULL
and	NULL
250	NULL
or	NULL
150	NULL
V	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
induced	NULL
with	NULL
3	NULL
x	NULL
10	NULL
®	NULL
m	NULL
TPA	NULL
(	NULL
Sigma	NULL
)	NULL
immediately	NULL
following	NULL
trans-fection	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
14	NULL
h	NULL
post	NULL
transfection	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
,	NULL
and	NULL
data	NULL
are	NULL
presented	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
growth	NULL
hormone	NULL
expressed	NULL
from	NULL
2	NULL
ug	NULL
of	NULL
cotransfected	NULL
plasmid	NULL
containing	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
directing	NULL
growth	NULL
hormone	NULL
expression	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Growth	NULL
hormone	NULL
concentrations	NULL
were	NULL
measured	NULL
by	NULL
radioimmunoassay	NULL
(	NULL
Nicol	NULL
's	NULL
Institute	NULL
,	NULL
San	NULL
Juan	NULL
Capistrano	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Nuclear	NULL
Extracts-The	NULL
human	NULL
promonocytic	NULL
cell	NULL
line	NULL
U937	NULL
(	NULL
ATCC	NULL
no	NULL
.	NULL

CRL	NULL
1593	NULL
)	NULL
was	NULL
grown	NULL
to	NULL
2	NULL
x	NULL
10°	NULL
cells/ml	NULL
and	NULL
induced	NULL
with	NULL
3	NULL
x	NULL
10~°	NULL
m	NULL
TPA	NULL
for	NULL
24	NULL
h	NULL
prior	NULL
to	NULL
harvest	NULL
for	NULL
nuclear	NULL
extraction	NULL
.	NULL

The	NULL
human	NULL
epithelial	NULL
carcinoma	NULL
cell	NULL
line	NULL
HeLa	NULL
(	NULL
ATCC	NULL
no	NULL
.	NULL

CCL	NULL
2	NULL
)	NULL
was	NULL
harvested	NULL
in	NULL
early	NULL
logarithmic	NULL
growth	NULL
phase	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
)	NULL
with	NULL
one	NULL
modification	NULL
;	NULL
the	NULL
following	NULL
protease	NULL
inhibitors	NULL
were	NULL
added	NULL
at	NULL
the	NULL
final	NULL
concentration	NULL
indicated	NULL
to	NULL
every	NULL
buffer	NULL
immediately	NULL
prior	NULL
to	NULL
use	NULL
:	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
ug/ml	NULL
pepstatin	NULL
A	NULL
,	NULL
0.5	NULL
ug/ml	NULL
chymostatin	NULL
,	NULL
1	NULL
ug/	NULL
ml	NULL
antipain	NULL
,	NULL
1	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
4	NULL
ul/ml	NULL
aprotinin	NULL
(	NULL
all	NULL
from	NULL
Sigma	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
using	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
)	NULL
and	NULL
bovine	NULL
serum	NULL
albumin	NULL
standards	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
lane	NULL
5	NULL
,	NULL
affinity	NULL
purified	NULL
Spl	NULL
protein	NULL
(	NULL
Promega	NULL
)	NULL
was	NULL
used	NULL
instead	NULL
of	NULL
nuclear	NULL
extract	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
(	NULL
EMSA	NULL
)	NULL
-The	NULL
probe	NULL
for	NULL
the	NULL
EMSAs	NULL
in	NULL
Figs	NULL
.	NULL

2	NULL
,	NULL
a	NULL
and	NULL
c	NULL
,	NULL
and	NULL
3	NULL
was	NULL
a	NULL
130-bp	NULL
BanI/BbsI	NULL
fragment	NULL
which	NULL
extends	NULL
from	NULL
bp	NULL
-90	NULL
to	NULL
bp	NULL
+40	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
generated	NULL
by	NULL
restriction	NULL
digestion	NULL
,	NULL
dephosphorylation	NULL
,	NULL
and	NULL
5	NULL
end	NULL
labeling	NULL
(	NULL
[	NULL
y-	NULL
``	NULL
P	NULL
]	NULL
ATP	NULL
,	NULL
NEN	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
of	NULL
the	NULL
resulting	NULL
fragments	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
30-bp	NULL
double-stranded	NULL
oligonucleotides	NULL
(	NULL
for	NULL
sequences	NULL
see	NULL
Fig	NULL
.	NULL

20	NULL
)	NULL
,	NULL
labeled	NULL
at	NULL
the	NULL
5	NULL
ends	NULL
using	NULL
[	NULL
y-P	NULL
]	NULL
ATP	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
.	NULL

0.5	NULL
ng	NULL
of	NULL
probe	NULL
at	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
cpm/ug	NULL
(	NULL
DNA	NULL
fragments	NULL
)	NULL
or	NULL
2	NULL
x	NULL
10°	NULL
cpm/ug	NULL
(	NULL
oligonucleotides	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
in	NULL
20	NULL
ul	NULL
containing	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
5	NULL
mM	NULL
MgC	NULL
)	NULL
;	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
5	NULL
%	NULL
glycerol	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Unlabeled	NULL
competitor	NULL
DNA	NULL
fragments	NULL
or	NULL
oligonucleotides	NULL
were	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
at	NULL
50-fold	NULL
molar	NULL
excess	NULL
immediately	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
radioactive	NULL
probe	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
7	NULL
,	NULL
the	NULL
competitor	NULL
DNA	NULL
consists	NULL
of	NULL
a	NULL
97-bp	NULL
HindIII/PstlI	NULL
fragment	NULL
from	NULL
the	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
promoter	NULL
,	NULL
which	NULL
contains	NULL
two	NULL
characterized	NULL
Spl	NULL
sites	NULL
(	NULL
Ref	NULL
.	NULL

18	NULL
;	NULL
for	NULL
partial	NULL
sequence	NULL
,	NULL
see	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
(	NULL
2892-E	NULL
)	NULL
,	NULL
raised	NULL
against	NULL
bacterially	NULL
expressed	NULL
human	NULL
Spl	NULL
(	NULL
18	NULL
)	NULL
,	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
Stephen	NULL
Jackson	NULL
,	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
.	NULL

3	NULL
Ll	NULL
of	NULL
antiserum	NULL
or	NULL
preimmune	NULL
serum	NULL
(	NULL
2892-pI	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
immediately	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
radioactive	NULL
probe	NULL
.	NULL

Reactions	NULL
were	NULL
electrophoresed	NULL
at	NULL
14	NULL
V/cm	NULL
on	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
cast	NULL
in	NULL
0.5	NULL
X	NULL
TBE	NULL
(	NULL
45	NULL
mM	NULL
Tris-borate	NULL
,	NULL
45	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

In	NULL
order	NULL
to	NULL
achieve	NULL
adequate	NULL
separation	NULL
of	NULL
bands	NULL
,	NULL
gels	NULL
were	NULL
run	NULL
sufficiently	NULL
long	NULL
so	NULL
that	NULL
unincor-porated	NULL
probe	NULL
was	NULL
run	NULL
off	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
gels	NULL
electrophoresed	NULL
for	NULL
shorter	NULL
time	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2¢	NULL
)	NULL
.	NULL

Methylation	NULL
Interference	NULL
Assays	NULL
of	NULL
Protein-DNA	NULL
Contacts-Meth-ylation	NULL
interference	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
with	NULL
minor	NULL
modifications	NULL
.	NULL

50	NULL
ng	NULL
of	NULL
an	NULL
oligonucleotide	NULL
,	NULL
extending	NULL
from	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
wt	NULL
-78	NULL
,	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
,	NULL
or	NULL
its	NULL
complement	NULL
was	NULL
5	NULL
end-labeled	NULL
with	NULL
[	NULL
y-*°P	NULL
]	NULL
ATP	NULL
to	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
2	NULL
x	NULL
10°	NULL
cpm/ug	NULL
.	NULL

The	NULL
labeled	NULL
oligonucleotide	NULL
was	NULL
annealed	NULL
with	NULL
2.5	NULL
ug	NULL
of	NULL
its	NULL
complementary	NULL
oligonucleotide	NULL
in	NULL
20	NULL
ul	NULL
containing	NULL
20	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
10	NULL
mM	NULL
MgCl	NULL
;	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
heated	NULL
to	NULL
45	NULL
°C	NULL
for	NULL
5	NULL
min	NULL
and	NULL
then	NULL
allowed	NULL
to	NULL
cool	NULL
slowly	NULL
to	NULL
room	NULL
temperature	NULL
over	NULL
2	NULL
h	NULL
and	NULL
incubated	NULL
overnight	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Annealed	NULL
double-stranded	NULL
oligonucleotide	NULL
,	NULL
labeled	NULL
on	NULL
one	NULL
end	NULL
,	NULL
was	NULL
purified	NULL
on	NULL
a	NULL
15	NULL
%	NULL
nondenaturing	NULL
acrylamide	NULL
gel	NULL
,	NULL
and	NULL
the	NULL
top	NULL
band	NULL
(	NULL
annealed	NULL
probe	NULL
)	NULL
isolated	NULL
by	NULL
the	NULL
``	NULL
crush	NULL
and	NULL
soak	NULL
``	NULL
method	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
annealed	NULL
probe	NULL
(	NULL
10-50	NULL
ng	NULL
)	NULL
was	NULL
treated	NULL
with	NULL
1	NULL
ul	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
for	NULL
5	NULL
min	NULL
at	NULL
20	NULL
°C	NULL
in	NULL
200	NULL
Ll	NULL
8231	NULL
of	NULL
50	NULL
mM	NULL
sodium	NULL
cacodylate	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8.0	NULL
.	NULL

2	NULL
ng	NULL
of	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
either	NULL
5	NULL
ug	NULL
of	NULL
U937	NULL
nuclear	NULL
extract	NULL
or	NULL
0.5	NULL
footprinting	NULL
units	NULL
(	NULL
Promega	NULL
)	NULL
of	NULL
affinity	NULL
purified	NULL
Spl	NULL
protein	NULL
in	NULL
a	NULL
preparative	NULL
mobility	NULL
shift	NULL
assay	NULL
as	NULL
described	NULL
above	NULL
.	NULL

DNA	NULL
protein	NULL
complexes	NULL
and	NULL
free	NULL
(	NULL
unbound	NULL
)	NULL
probe	NULL
were	NULL
isolated	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
of	NULL
the	NULL
labeled	NULL
DNA	NULL
cut	NULL
from	NULL
the	NULL
polyacrylamide	NULL
gel	NULL
onto	NULL
DEAE	NULL
mem-branes	NULL
.	NULL

Methylated	NULL
residues	NULL
were	NULL
cleaved	NULL
with	NULL
10	NULL
%	NULL
piperidine	NULL
at	NULL
90°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
the	NULL
methylation	NULL
pattern	NULL
analyzed	NULL
on	NULL
15	NULL
%	NULL
sequencing	NULL
gels	NULL
followed	NULL
by	NULL
autoradiography	NULL
at	NULL
-80	NULL
°C	NULL
with	NULL
intensifying	NULL
screens	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
CD11b	NULL
Promoter	NULL
in	NULL
Drosophila	NULL
Schneider	NULL
Cells-The	NULL
Drosophila	NULL
Schneider	NULL
cell	NULL
line	NULL
$	NULL
2	NULL
was	NULL
grown	NULL
in	NULL
Schneider	NULL
medium	NULL
(	NULL
Sigma	NULL
)	NULL
supplemented	NULL
with	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Hyclone	NULL
)	NULL
.	NULL

For	NULL
transactivation	NULL
assays	NULL
,	NULL
S2	NULL
cells	NULL
were	NULL
transfected	NULL
using	NULL
calcium	NULL
phosphate	NULL
coprecipi-tation	NULL
as	NULL
described	NULL
(	NULL
21	NULL
)	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
reporter	NULL
vector	NULL
(	NULL
either	NULL
the	NULL
wild	NULL
type	NULL
-412	NULL
CD11b	NULL
promoter	NULL
or	NULL
the	NULL
promoter	NULL
containing	NULL
a	NULL
2-bp	NULL
mutation	NULL
in	NULL
the	NULL
Sp1	NULL
site	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
11	NULL
;	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
;	NULL
3	NULL
ug	NULL
of	NULL
the	NULL
Sp1	NULL
expression	NULL
vector	NULL
pPacSpl	NULL
,	NULL
containing	NULL
the	NULL
C-terminal	NULL
696	NULL
amino	NULL
acids	NULL
of	NULL
Spl	NULL
in	NULL
a	NULL
Drosophila	NULL
actin	NULL
promoter	NULL
expression	NULL
construct	NULL
(	NULL
22	NULL
)	NULL
;	NULL
10	NULL
ug	NULL
of	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
directing	NULL
growth	NULL
hormone	NULL
expression	NULL
(	NULL
16	NULL
)	NULL
;	NULL
and	NULL
KS+	NULL
pBluescript	NULL
(	NULL
Stratagene	NULL
)	NULL
to	NULL
a	NULL
total	NULL
of	NULL
25	NULL
ug	NULL
of	NULL
DNA	NULL
.	NULL

In	NULL
control	NULL
experiments	NULL
,	NULL
the	NULL
pPac§Sp1	NULL
construct	NULL
was	NULL
replaced	NULL
by	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
expression	NULL
vector	NULL
pSG5RARa	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
14	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
Footprinting-For	NULL
in	NULL
vitro	NULL
footprinting	NULL
,	NULL
a	NULL
370-bp	NULL
fragment	NULL
extending	NULL
from	NULL
the	NULL
EcoRI	NULL
site	NULL
at	NULL
bp	NULL
-264	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
to	NULL
the	NULL
Hpal	NULL
site	NULL
at	NULL
bp	NULL
+106	NULL
(	NULL
11	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
pGEM	NULL
3zf	NULL
(	NULL
+	NULL
)	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
HindIII	NULL
to	NULL
release	NULL
the	NULL
insert	NULL
,	NULL
which	NULL
was	NULL
radioactively	NULL
labeled	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
(	NULL
coding	NULL
strand	NULL
)	NULL
or	NULL
the	NULL
EcoRI	NULL
site	NULL
(	NULL
non-coding	NULL
strand	NULL
)	NULL
using	NULL
[	NULL
a-*	NULL
``	NULL
P	NULL
]	NULL
dATP	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

80	NULL
ug	NULL
of	NULL
HeLa	NULL
or	NULL
U937	NULL
cell	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
DNA	NULL
probe	NULL
,	NULL
labeled	NULL
to	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
1.5	NULL
x	NULL
10°	NULL
cpm/ug	NULL
,	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Promega	NULL
)	NULL
in	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
30	NULL
mm	NULL
KCI	NULL
,	NULL
12	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
;	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
0.2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
cleaved	NULL
with	NULL
180	NULL
ng	NULL
of	NULL
DNase	NULL
I	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
1	NULL
min	NULL
.	NULL

Reactions	NULL
were	NULL
terminated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
100	NULL
«	NULL
1	NULL
of	NULL
stop	NULL
solution	NULL
(	NULL
20	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
%	NULL
SDS	NULL
,	NULL
20	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
75	NULL
ug/ml	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
,	NULL
100	NULL
ug/ml	NULL
proteinase	NULL
K	NULL
)	NULL
and	NULL
subsequent	NULL
incubation	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Reactions	NULL
were	NULL
extracted	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
phenol-chloroform	NULL
,	NULL
ethanol	NULL
precipitated	NULL
,	NULL
and	NULL
products	NULL
analyzed	NULL
on	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Chemical	NULL
sequencing	NULL
reactions	NULL
(	NULL
20	NULL
)	NULL
of	NULL
the	NULL
same	NULL
DNA	NULL
were	NULL
used	NULL
as	NULL
size	NULL
standards	NULL
.	NULL

In	NULL
Vivo	NULL
Footprinting-¥For	NULL
in	NULL
vivo	NULL
methylation	NULL
studies	NULL
in	NULL
cell	NULL
lines	NULL
,	NULL
10°	NULL
uninduced	NULL
or	NULL
TPA	NULL
induced	NULL
(	NULL
24	NULL
h	NULL
at	NULL
3	NULL
x	NULL
10~°	NULL
m	NULL
)	NULL
U937	NULL
cells	NULL
or	NULL
HeLa	NULL
cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
500	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
and	NULL
resuspended	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
RPMI	NULL
medium	NULL
.	NULL

Human	NULL
monocytes	NULL
and	NULL
lymphocytes	NULL
were	NULL
purified	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
normal	NULL
donors	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
and	NULL
separated	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
.	NULL

Cells	NULL
were	NULL
exposed	NULL
to	NULL
0.5	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
dimethyl	NULL
sulfide	NULL
(	NULL
Sigma	NULL
)	NULL
for	NULL
4	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
DNA	NULL
extracted	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
footprints	NULL
were	NULL
visualized	NULL
using	NULL
the	NULL
ligation-mediated-PCR	NULL
procedure	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
universal	NULL
linker	NULL
used	NULL
in	NULL
this	NULL
amplification	NULL
method	NULL
is	NULL
composed	NULL
of	NULL
two	NULL
oligonucleotides	NULL
:	NULL
linker	NULL
oligo	NULL
1	NULL
:	NULL
GAATTCAGATC	NULL
;	NULL
linker	NULL
oligo	NULL
2	NULL
:	NULL
GCGGTGACCCGGGA-GATCTGAATTC	NULL
.	NULL

The	NULL
specific	NULL
oligonucleotides	NULL
from	NULL
the	NULL
CD1lb	NULL
promoter	NULL
region	NULL
coding	NULL
strand	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
oligo	NULL
1	NULL
,	NULL
used	NULL
for	NULL
first	NULL
strand	NULL
transcription	NULL
,	NULL
bp	NULL
-196	NULL
to	NULL
-172	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
:	NULL
GTGACAAATGGCACCTTTTGGATAG	NULL
;	NULL
oligo	NULL
2	NULL
,	NULL
used	NULL
for	NULL
PCR	NULL
amplification	NULL
,	NULL
bp	NULL
-156	NULL
to	NULL
bp	NULL
-132	NULL
;	NULL
AAGTTTGGGTCAGGA-AGCTGGGGAG	NULL
;	NULL
and	NULL
oligo	NULL
3	NULL
,	NULL
kinased	NULL
with	NULL
[	NULL
y-*P	NULL
]	NULL
ATP	NULL
and	NULL
used	NULL
in	NULL
primer	NULL
extension	NULL
for	NULL
visualization	NULL
of	NULL
PCR	NULL
products	NULL
,	NULL
bp	NULL
-149	NULL
to	NULL
bp	NULL
-124	NULL
;	NULL
GGTCAGGAAGCTGGGGAGGAAGGGTG	NULL
.	NULL

Specific	NULL
oligonucleotides	NULL
for	NULL
the	NULL
CD11b	NULL
noncoding	NULL
strand	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
oligo	NULL
1	NULL
,	NULL
used	NULL
for	NULL
first	NULL
strand	NULL
transcription	NULL
,	NULL
bp	NULL
+108	NULL
to	NULL
+84	NULL
:	NULL
TTAACAGAAG-GACTCTGAGAGCCAT	NULL
;	NULL
oligo	NULL
2	NULL
,	NULL
used	NULL
for	NULL
PCR	NULL
amplification	NULL
,	NULL
bp	NULL
+80	NULL
to	NULL
bp	NULL
+56	NULL
:	NULL
TGGAAGGAGCCAGAACCTGGAAGGA	NULL
;	NULL
and	NULL
oligo	NULL
3	NULL
,	NULL
kinased	NULL
with	NULL
[	NULL
y-P	NULL
]	NULL
JATP	NULL
and	NULL
used	NULL
in	NULL
primer	NULL
extension	NULL
for	NULL
visualization	NULL
of	NULL
PCR	NULL
products	NULL
,	NULL
bp	NULL
+78	NULL
to	NULL
bp	NULL
+52	NULL
:	NULL
GAAGGAGCCAGA-ACCTGGAAGGAGGTG	NULL
.	NULL

All	NULL
oligonucleotides	NULL
were	NULL
purified	NULL
by	NULL
electrophoresis	NULL
on	NULL
15	NULL
%	NULL
nondenaturing	NULL
acrylamide	NULL
gels	NULL
followed	NULL
by	NULL
purification	NULL
using	NULL
Elutip-D	NULL
(	NULL
Schleicher	NULL
&	NULL
-	NULL
Schuell	NULL
)	NULL
columns	NULL
.	NULL
``	NULL

Autoradiographs	NULL
exposed	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
of	NULL
the	NULL
film	NULL
were	NULL
scanned	NULL
*	NULL
H.-M.	NULL
Chen	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
.	NULL

8232	NULL
with	NULL
an	NULL
LKB	NULL
XL	NULL
laser	NULL
densitometer	NULL
.	NULL

Ligation-mediated-PCR	NULL
extensions	NULL
stop	NULL
at	NULL
C	NULL
residues	NULL
because	NULL
the	NULL
template	NULL
ends	NULL
at	NULL
a	NULL
methylated	NULL
and	NULL
cleaved	NULL
complementary	NULL
G	NULL
residue	NULL
;	NULL
the	NULL
footprinting	NULL
gel	NULL
shows	NULL
bands	NULL
at	NULL
sequences	NULL
corresponding	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
cytosines	NULL
in	NULL
the	NULL
sequence	NULL
of	NULL
one	NULL
strand	NULL
but	NULL
implies	NULL
methylation	NULL
at	NULL
the	NULL
corresponding	NULL
guanosine	NULL
residues	NULL
on	NULL
the	NULL
complementary	NULL
strand	NULL
.	NULL

RESULTS	NULL
Linker	NULL
Scanning	NULL
Analysis	NULL
of	NULL
the	NULL
CD11b	NULL
-92	NULL
bp	NULL
Promoter	NULL
Reveals	NULL
an	NULL
Essential	NULL
Region	NULL
Centered	NULL
at	NULL
bp	NULL
-60-In	NULL
order	NULL
to	NULL
determine	NULL
sequences	NULL
required	NULL
for	NULL
CD11b	NULL
promoter	NULL
activity	NULL
,	NULL
we	NULL
constructed	NULL
nine	NULL
linker	NULL
scanning	NULL
mutations	NULL
by	NULL
inserting	NULL
a	NULL
10-bp	NULL
oligonucleotide	NULL
linker	NULL
consecutively	NULL
every	NULL
10	NULL
bp	NULL
in	NULL
the	NULL
promoter	NULL
(	NULL
for	NULL
sequences	NULL
,	NULL
see	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
.	NULL

We	NULL
tested	NULL
these	NULL
constructs	NULL
by	NULL
transient	NULL
transfection	NULL
into	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
mutation	NULL
of	NULL
bp	NULL
-12	NULL
to	NULL
-15	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
disrupts	NULL
a	NULL
PU.1	NULL
binding	NULL
site	NULL
and	NULL
decreases	NULL
the	NULL
92-bp	NULL
promoter	NULL
activity	NULL
3-fold	NULL
(	NULL
12	NULL
)	NULL
.	NULL

This	NULL
result	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
linker	NULL
scanning	NULL
mutant	NULL
-15/-5	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
)	NULL
,	NULL
which	NULL
retains	NULL
only	NULL
54	NULL
%	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
promoter	NULL
activity	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
CD11b	NULL
promoter	NULL
activity	NULL
was	NULL
seen	NULL
when	NULL
sequences	NULL
between	NULL
bp	NULL
-65	NULL
and	NULL
-55	NULL
,	NULL
bp	NULL
-55	NULL
and	NULL
-45	NULL
and	NULL
bp	NULL
-45	NULL
and	NULL
-35	NULL
were	NULL
replaced	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
)	NULL
.	NULL

Since	NULL
these	NULL
constructs	NULL
carry	NULL
mutations	NULL
at	NULL
adjacent	NULL
sequences	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
they	NULL
may	NULL
each	NULL
be	NULL
partially	NULL
disrupting	NULL
a	NULL
sequence	NULL
required	NULL
for	NULL
promoter	NULL
activity	NULL
.	NULL

Since	NULL
deletion	NULL
of	NULL
the	NULL
entire	NULL
region	NULL
may	NULL
have	NULL
a	NULL
greater	NULL
effect	NULL
on	NULL
CD11b	NULL
promoter	NULL
activity	NULL
than	NULL
the	NULL
individual	NULL
linker	NULL
scanning	NULL
mutations	NULL
,	NULL
we	NULL
constructed	NULL
an	NULL
additional	NULL
mutant	NULL
which	NULL
substituted	NULL
bp	NULL
-75	NULL
to	NULL
bp	NULL
-45	NULL
with	NULL
the	NULL
oligonucleotide	NULL
linker	NULL
.	NULL

This	NULL
mutant	NULL
retains	NULL
only	NULL
9	NULL
%	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
concluded	NULL
that	NULL
sequences	NULL
between	NULL
bp	NULL
-75	NULL
and	NULL
-35	NULL
are	NULL
essential	NULL
for	NULL
CD11b	NULL
promoter	NULL
activity	NULL
and	NULL
investigated	NULL
whether	NULL
transcription	NULL
factors	NULL
bound	NULL
these	NULL
sequences	NULL
.	NULL

The	NULL
Transcription	NULL
Factor	NULL
Sp1	NULL
Binds	NULL
the	NULL
CD11b	NULL
Promoter	NULL
at	NULL
bp	NULL
-60-We	NULL
used	NULL
an	NULL
EMSA	NULL
to	NULL
investigate	NULL
DNA-protein	NULL
interactions	NULL
in	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
U937	NULL
(	NULL
myeloid	NULL
)	NULL
or	NULL
HeLa	NULL
(	NULL
non-myeloid	NULL
)	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
130-bp	NULL
probe	NULL
,	NULL
which	NULL
extends	NULL
from	NULL
bp	NULL
-90	NULL
to	NULL
bp	NULL
+40	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
previously	NULL
characterized	NULL
complex	NULL
formed	NULL
by	NULL
PU.1	NULL
(	NULL
12	NULL
)	NULL
(	NULL
marked	NULL
PU.1	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
a	NULL
and	NULL
c	NULL
)	NULL
,	NULL
two	NULL
complexes	NULL
(	NULL
marked	NULL
A	NULL
and	NULL
A	NULL
``	NULL
)	NULL
specifically	NULL
bind	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

PU.1	NULL
is	NULL
identified	NULL
because	NULL
the	NULL
complex	NULL
is	NULL
competed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
PU.1	NULL
site	NULL
,	NULL
bp	NULL
-26	NULL
to	NULL
+2	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
12	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
addition	NULL
of	NULL
oligonucleotides	NULL
spanning	NULL
either	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
bp	NULL
-114	NULL
to	NULL
-85	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
band	NULL
immediately	NULL
above	NULL
the	NULL
PU.1	NULL
band	NULL
represents	NULL
nonspecific	NULL
binding	NULL
to	NULL
the	NULL
probe	NULL
,	NULL
as	NULL
it	NULL
can	NULL
not	NULL
be	NULL
competed	NULL
by	NULL
excess	NULL
non-radioactive	NULL
self	NULL
competitor	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Contrary	NULL
to	NULL
the	NULL
PU.1	NULL
complex	NULL
,	NULL
which	NULL
is	NULL
seen	NULL
only	NULL
in	NULL
U937	NULL
cell	NULL
extracts	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
8	NULL
;	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
complexes	NULL
A	NULL
and	NULL
A	NULL
``	NULL
are	NULL
present	NULL
in	NULL
both	NULL
U937	NULL
and	NULL
HeLa	NULL
cell	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
8	NULL
;	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
;	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

They	NULL
are	NULL
competed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
non-radioactive	NULL
130-bp	NULL
CD11b	NULL
promoter	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
as	NULL
well	NULL
as	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
of	NULL
the	NULL
promoter	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

20	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
;	NULL
and	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

A	NULL
second	NULL
oligonucleotide	NULL
,	NULL
also	NULL
spanning	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
,	NULL
but	NULL
containing	NULL
a	NULL
2-bp	NULL
mutation	NULL
at	NULL
bp	NULL
-60	NULL
and	NULL
-61	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
,	NULL
no	NULL
longer	NULL
competes	NULL
the	NULL
binding	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
A	NULL
``	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lane	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
whereas	NULL
the	NULL
mutant	NULL
oligonucleotide	NULL
,	NULL
when	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
binds	NULL
neither	NULL
band	NULL
A	NULL
nor	NULL
A	NULL
'	NULL
,	NULL
the	NULL
wild	NULL
type	NULL
oligonucleotide	NULL
binds	NULL
both	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
immediately	NULL
surrounding	NULL
bp	NULL
-60	NULL
and	NULL
-61	NULL
,	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
and	NULL
thus	NULL
implicated	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
A*	NULL
,	NULL
5'-CCGCCC-3	NULL
'	NULL
,	NULL
is	NULL
found	NULL
also	NULL
at	NULL
bp	NULL
-100	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
bp	NULL
-114	NULL
to	NULL
-85	NULL
neither	NULL
competes	NULL
for	NULL
binding	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
A	NULL
``	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
4	NULL
;	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
nor	NULL
does	NULL
it	NULL
itself	NULL
bind	NULL
the	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
sequence	NULL
between	NULL
bp	NULL
-64	NULL
and	NULL
-59	NULL
,	NULL
constitutes	NULL
a	NULL
consensus	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
complex	NULL
A	NULL
and	NULL
A	NULL
``	NULL
represent	NULL
Sp1	NULL
binding	NULL
by	NULL
competing	NULL
with	NULL
a	NULL
97-bp	NULL
DNA	NULL
fragment	NULL
of	NULL
the	NULL
tissue	NULL
plasminogen	NULL
promoter	NULL
(	NULL
18	NULL
)	NULL
containing	NULL
two	NULL
characterized	NULL
Sp1-binding	NULL
sites	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

2a	NULL
,	NULL
lane	NULL
7	NULL
,	NULL
shows	NULL
that	NULL
both	NULL
complexes	NULL
A	NULL
and	NULL
A	NULL
``	NULL
,	NULL
but	NULL
not	NULL
the	NULL
PU.1	NULL
complex	NULL
,	NULL
are	NULL
competed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
DNA	NULL
containing	NULL
Sp1-binding	NULL
sites	NULL
,	NULL
suggesting	NULL
that	NULL
they	NULL
represent	NULL
Spl	NULL
binding	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
complex	NULL
A	NULL
consists	NULL
only	NULL
of	NULL
the	NULL
Spl	NULL
transcription	NULL
factor	NULL
or	NULL
perhaps	NULL
contains	NULL
additional	NULL
DNA-binding	NULL
proteins	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
binding	NULL
of	NULL
purified	NULL
Spl	NULL
and	NULL
nuclear	NULL
extracts	NULL
in	NULL
an	NULL
EMSA	NULL
.	NULL

Fig	NULL
.	NULL

2¢	NULL
shows	NULL
that	NULL
when	NULL
purified	NULL
Sp1	NULL
protein	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
is	NULL
bound	NULL
to	NULL
the	NULL
CD11b	NULL
promoter	NULL
bp	NULL
-90	NULL
to	NULL
+40	NULL
probe	NULL
,	NULL
the	NULL
predominant	NULL
binding	NULL
activity	NULL
co-migrates	NULL
with	NULL
complex	NULL
A	NULL
formed	NULL
by	NULL
extracts	NULL
from	NULL
U937	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
faint	NULL
bands	NULL
above	NULL
the	NULL
predominant	NULL
band	NULL
in	NULL
lane	NULL
5	NULL
(	NULL
purified	NULL
Sp1	NULL
)	NULL
are	NULL
also	NULL
visible	NULL
in	NULL
lane	NULL
1	NULL
,	NULL
in	NULL
which	NULL
U937	NULL
nuclear	NULL
extracts	NULL
are	NULL
used	NULL
,	NULL
and	NULL
,	NULL
on	NULL
longer	NULL
exposure	NULL
of	NULL
the	NULL
gel	NULL
,	NULL
in	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
,	NULL
in	NULL
which	NULL
nuclear	NULL
extracts	NULL
from	NULL
HeLa	NULL
cells	NULL
are	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
complexes	NULL
are	NULL
competed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
wild	NULL
type	NULL
bp	NULL
-78	NULL
oligonucleotide	NULL
,	NULL
as	NULL
lane	NULL
3	NULL
shows	NULL
no	NULL
bands	NULL
even	NULL
on	NULL
long	NULL
exposure	NULL
of	NULL
the	NULL
gel	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
slowly	NULL
migrating	NULL
bands	NULL
thus	NULL
most	NULL
likely	NULL
represent	NULL
multimeric	NULL
complexes	NULL
of	NULL
Spl	NULL
binding	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

Multimeric	NULL
binding	NULL
of	NULL
Spl	NULL
has	NULL
been	NULL
observed	NULL
on	NULL
other	NULL
promoters	NULL
(	NULL
18	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
complex	NULL
A	NULL
consists	NULL
only	NULL
of	NULL
the	NULL
Spl	NULL
protein	NULL
bound	NULL
to	NULL
the	NULL
CD11b	NULL
promoter	NULL
and	NULL
does	NULL
not	NULL
contain	NULL
additional	NULL
DNA-bind-ing	NULL
proteins	NULL
.	NULL

In	NULL
order	NULL
to	NULL
confirm	NULL
that	NULL
complexes	NULL
A	NULL
and	NULL
A*	NULL
represent	NULL
Sp1	NULL
binding	NULL
,	NULL
we	NULL
used	NULL
an	NULL
antiserum	NULL
against	NULL
Spl	NULL
,	NULL
which	NULL
was	NULL
previously	NULL
shown	NULL
to	NULL
induce	NULL
``	NULL
supershifts	NULL
``	NULL
of	NULL
Spl	NULL
complexes	NULL
in	NULL
an	NULL
EMSA	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
shows	NULL
that	NULL
addition	NULL
of	NULL
anti-Sp1	NULL
antiserum	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
but	NULL
not	NULL
preimmune	NULL
serum	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
results	NULL
in	NULL
a	NULL
``	NULL
supershift	NULL
``	NULL
(	NULL
marked	NULL
S	NULL
)	NULL
of	NULL
band	NULL
A	NULL
,	NULL
confirming	NULL
that	NULL
band	NULL
A	NULL
represents	NULL
Spl	NULL
binding	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

Complex	NULL
A	NULL
``	NULL
does	NULL
not	NULL
supershift	NULL
after	NULL
addition	NULL
of	NULL
anti-Spl	NULL
antiserum	NULL
;	NULL
this	NULL
complex	NULL
may	NULL
represent	NULL
a	NULL
proteolytically	NULL
cleaved	NULL
form	NULL
of	NULL
Spl	NULL
,	NULL
which	NULL
is	NULL
not	NULL
recognized	NULL
by	NULL
the	NULL
antibody	NULL
,	NULL
a	NULL
differentially	NULL
glycosylated	NULL
form	NULL
of	NULL
Spl	NULL
(	NULL
28	NULL
)	NULL
,	NULL
or	NULL
it	NULL
may	NULL
represent	NULL
a	NULL
second	NULL
,	NULL
distinct	NULL
protein	NULL
binding	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

In	NULL
order	NULL
to	NULL
distinguish	NULL
these	NULL
possibilities	NULL
,	NULL
we	NULL
performed	NULL
methylation	NULL
interference	NULL
assays	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
oligonucleotide	NULL
(	NULL
wt	NULL
-78	NULL
,	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
was	NULL
end	NULL
labeled	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
with	NULL
[	NULL
y-P	NULL
]	NULL
ATP	NULL
,	NULL
annealed	NULL
with	NULL
its	NULL
complementary	NULL
oligonucleotide	NULL
,	NULL
treated	NULL
with	NULL
limiting	NULL
amounts	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
,	NULL
and	NULL
then	NULL
used	NULL
in	NULL
a	NULL
preparative	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Dimethyl	NULL
sulfate	NULL
methylates	NULL
N-7	NULL
of	NULL
guanines	NULL
in	NULL
the	NULL
major	NULL
groove	NULL
of	NULL
a	NULL
DNA	NULL
double	NULL
helix	NULL
,	NULL
interfering	NULL
with	NULL
protein	NULL
binding	NULL
at	NULL
this	NULL
site	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Partially	NULL
methylated	NULL
DNA	NULL
was	NULL
subjected	NULL
to	NULL
a	NULL
preparative	NULL
mobility	NULL
shift	NULL
assay	NULL
,	NULL
and	NULL
DNA	NULL
bound	NULL
in	NULL
complexes	NULL
A	NULL
and	NULL
A*	NULL
as	NULL
well	NULL
as	NULL
unbound	NULL
DNA	NULL
subjected	NULL
to	NULL
cleavage	NULL
with	NULL
piperidine	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
demonstrates	NULL
that	NULL
complexes	NULL
A	NULL
and	NULL
A	NULL
``	NULL
made	NULL
identical	NULL
contacts	NULL
on	NULL
2	NULL
G	NULL
residues	NULL
within	NULL
the	NULL
binding	NULL
region	NULL
(	NULL
bp	NULL
-62	NULL
and	NULL
-68	NULL
)	NULL
.	NULL

The	NULL
same	NULL
preparation	NULL
of	NULL
affinity	NULL
purified	NULL
Spl	NULL
used	NULL
in	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
lane	NULL
5	NULL
,	NULL
made	NULL
precisely	NULL
the	NULL
same	NULL
two	NULL
contacts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
experiments	NULL
performed	NULL
with	NULL
DNA	NULL
end	NULL
labeled	NULL
on	NULL
the	NULL
complementary	NULL
noncoding	NULL
oligonucleotide	NULL
demonstrated	NULL
that	NULL
complexes	NULL
A	NULL
and	NULL
A*	NULL
made	NULL
00	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
luciferase	NULL
=	NULL
--	NULL
--	NULL
--	NULL
£22277777	NULL
%	NULL
Activity	NULL
0	NULL
,	NULL
haz	NULL
R	NULL
20	NULL
eo	NULL
-	NULL
so	NULL
%	NULL
Activity	NULL
LU	NULL
&	NULL
\\\\\\\\\\\\W	NULL
100	NULL
_	NULL
1sezo	NULL
95/-85	NULL
[	NULL
|	NULL
61+/-22	NULL
_	NULL
8492	NULL
/-	NULL
3062	NULL
85/-75	NULL
[	NULL
_	NULL
]	NULL
\\\\\	NULL
\\\\	NULL
84	NULL
+/-	NULL
28	NULL
_	NULL
11692	NULL
+/-	NULL
3897	NULL
\	NULL
\\\\\\\\\	NULL
74	NULL
+/-	NULL
24	NULL
_	NULL
10300	NULL
+/-	NULL
3340	NULL
-65/-55	NULL
S	NULL
19	NULL
+/-7	NULL
_	NULL
2645	NULL
+/-	NULL
1044	NULL
757-45	NULL
-	NULL
U	NULL
9	NULL
+3	NULL
-	NULL
1253	NULL
+/-	NULL
417	NULL
-55/-45	NULL
27	NULL
i/-	NULL
5	NULL
_	NULL
3758	NULL
+/-	NULL
696	NULL
-45/-35	NULL
42	NULL
+/-	NULL
10	NULL
__	NULL
5846	NULL
+/-	NULL
1392	NULL
-35/-25	NULL
127	NULL
+/-	NULL
44	NULL
_	NULL
17678	NULL
+/-	NULL
6124	NULL
-25/-15	NULL
108	NULL
+/-	NULL
21	NULL
_	NULL
15037	NULL
+/-	NULL
2923	NULL
45/5	NULL
54	NULL
+/-	NULL
28	NULL
_	NULL
7517	NULL
+/-	NULL
3201	NULL
b	NULL
CD11b	NULL
-95/-85	NULL
wild	NULL
type	NULL
GaCCAGGCAG	NULL
CD11b	NULL
-95/-8	NULL
$	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
90	NULL
%	NULL
CDL1b	NULL
-85/-75	NULL
wild	NULL
type	NULL
GGCTaTGTGC	NULL
CD11b	NULL
-85/-75	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
60	NULL
%	NULL
CDL1b	NULL
-75/-65	NULL
wild	NULL
type	NULL
TCACTGAGCC	NULL
90	NULL
%	NULL
CD11b	NULL
-75/-65	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
©	NULL
CDL1b	NULL
-65/-55	NULL
wild	NULL
type	NULL
TCCGCCCTCT	NULL
70	NULL
%	NULL
CD11b	NULL
-65/-55	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
°	NULL
CD11b	NULL
-55/-45	NULL
wild	NULL
type	NULL
TCCTTTGAAT	NULL
90	NULL
%	NULL
CD1L1b	NULL
-55/-45	NULL
linker	NULL
sean	NULL
-__	NULL
GGATCCCAGA	NULL
o	NULL
CD11b	NULL
-45/-35	NULL
wild	NULL
type	NULL
CTCTGATAGA	NULL
60	NULL
%	NULL
CD11b	NULL
-45/-35	NULL
linker	NULL
sean	NULL
___	NULL
GGATCCCAGA	NULL
°	NULL
CD11b	NULL
-35/-25	NULL
wild	NULL
type	NULL
ertctaeere	NULL
90	NULL
CD11b	NULL
-35/-25	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
%	NULL
-25/-15	NULL
wild	NULL
type	NULL
cractreree	NULL
0	NULL
CD11b	NULL
-25/-15	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
80	NULL
%	NULL
CD11b	NULL
-15/-5	NULL
wild	NULL
type	NULL
TTTTCTGCCC	NULL
CD11b	NULL
linker	NULL
scan	NULL
GGATCCCAGA	NULL
80	NULL
%	NULL
8233	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Linker	NULL
scanning	NULL
analysis	NULL
of	NULL
the	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
.	NULL

Panel	NULL
a	NULL
,	NULL
transient	NULL
transfections	NULL
of	NULL
the	NULL
92-bp	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
and	NULL
10	NULL
linker	NULL
scanning	NULL
mutants	NULL
into	NULL
TPA-induced	NULL
U937	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
schematic	NULL
,	NULL
lines	NULL
represent	NULL
wild	NULL
type	NULL
sequences	NULL
,	NULL
and	NULL
the	NULL
linker	NULL
oligonucleotide	NULL
is	NULL
represented	NULL
by	NULL
a	NULL
square	NULL
.	NULL

Four	NULL
independent	NULL
experiments	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
the	NULL
average	NULL
activities	NULL
and	NULL
standard	NULL
errors	NULL
relative	NULL
to	NULL
the	NULL
92-bp	NULL
wild	NULL
type	NULL
promoter	NULL
(	NULL
100	NULL
%	NULL
activity	NULL
)	NULL
were	NULL
calculated	NULL
.	NULL

The	NULL
average	NULL
luciferase	NULL
activity	NULL
is	NULL
reported	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
,	NULL
and	NULL
results	NULL
are	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Background	NULL
luciferase	NULL
activity	NULL
,	NULL
obtained	NULL
from	NULL
transfection	NULL
of	NULL
the	NULL
promoterless	NULL
pXP2	NULL
parent	NULL
plasmid	NULL
,	NULL
was	NULL
320	NULL
RLU	NULL
.	NULL

Panel	NULL
b	NULL
,	NULL
sequence	NULL
replacements	NULL
obtained	NULL
in	NULL
individual	NULL
linker	NULL
scanning	NULL
mutations	NULL
.	NULL

Sequence	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
and	NULL
the	NULL
linker	NULL
scanning	NULL
mutations	NULL
in	NULL
the	NULL
replaced	NULL
positions	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
percent	NULL
change	NULL
from	NULL
wild	NULL
type	NULL
sequence	NULL
is	NULL
depicted	NULL
on	NULL
the	NULL
right	NULL
.	NULL

identical	NULL
contacts	NULL
on	NULL
4	NULL
G	NULL
residues	NULL
within	NULL
the	NULL
binding	NULL
region	NULL
at	NULL
bp	NULL
-63	NULL
and	NULL
at	NULL
bp	NULL
-61	NULL
to	NULL
-59	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
complexes	NULL
A	NULL
,	NULL
A*	NULL
,	NULL
and	NULL
affinity	NULL
purified	NULL
Spl	NULL
bind	NULL
this	NULL
site	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
,	NULL
supporting	NULL
the	NULL
hypothesis	NULL
that	NULL
A	NULL
``	NULL
represents	NULL
a	NULL
derivative	NULL
of	NULL
complex	NULL
A	NULL
(	NULL
Sp1	NULL
)	NULL
.	NULL

The	NULL
Sp1	NULL
Site	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity-After	NULL
identifying	NULL
both	NULL
the	NULL
Spl-binding	NULL
site	NULL
in	NULL
the	NULL
CD11b	NULL
promoter	NULL
and	NULL
a	NULL
two-bp	NULL
mutation	NULL
,	NULL
which	NULL
no	NULL
longer	NULL
binds	NULL
Sp1	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
mutation	NULL
of	NULL
the	NULL
Sp1	NULL
site	NULL
entirely	NULL
accounts	NULL
for	NULL
the	NULL
loss	NULL
of	NULL
promoter	NULL
activity	NULL
seen	NULL
in	NULL
linker	NULL
scanning	NULL
mutations	NULL
-65/-55	NULL
,	NULL
-55/-45	NULL
,	NULL
-45/-35	NULL
,	NULL
and	NULL
-75/	NULL
-45	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

We	NULL
introduced	NULL
the	NULL
same	NULL
two-bp	NULL
mutation	NULL
of	NULL
the	NULL
Sp1	NULL
site	NULL
at	NULL
bp	NULL
-60	NULL
and	NULL
-61	NULL
into	NULL
the	NULL
412	NULL
bp	NULL
promoter	NULL
,	NULL
which	NULL
has	NULL
maximal	NULL
activity	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
(	NULL
11	NULL
)	NULL
,	NULL
and	NULL
transiently	NULL
transfected	NULL
both	NULL
the	NULL
wild	NULL
type	NULL
and	NULL
the	NULL
mutant	NULL
construct	NULL
into	NULL
U937	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
shows	NULL
that	NULL
in	NULL
U937	NULL
cells	NULL
,	NULL
the	NULL
two-bp	NULL
mutation	NULL
at	NULL
bp	NULL
-60	NULL
and	NULL
-61	NULL
causes	NULL
an	NULL
18-fold	NULL
decrease	NULL
over	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
activity	NULL
.	NULL

In	NULL
HeLa	NULL
8234	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
a	NULL
Probe	NULL
:	NULL
CD11b	NULL
bp	NULL
-90	NULL
to	NULL
+	NULL
40	NULL
Extract	NULL
:	NULL
U937	NULL
HeLa	NULL
j	NULL
-	NULL
wto	NULL
om	NULL
owt	NULL
wt	NULL
CD	NULL
tPA	NULL
__	NULL
Competltor	NULL
.	NULL

~~	NULL
O78	NULL
78	NULL
414	NULL
PU	NULL
11h	NULL
a	NULL
-	NULL
>	NULL
M	NULL
MWW	NULL
.	NULL

a	NULL
-	NULL
>	NULL
eme®**	NULL
PUA	NULL
-	NULL
]	NULL
if	NULL
.	NULL

“	NULL
Ki	NULL
Lanes	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
67	NULL
8	NULL
b	NULL
[	NULL
~	NULL
na	NULL
tara	NULL
Probe	NULL
:	NULL
|CD11b	NULL
bp-78	NULL
to	NULL
-49	NULL
Extract	NULL
:	NULL
]	NULL
HeLa	NULL
-	NULL
|U937	NULL
HeLa	NULL
!	NULL

e	NULL
Competitor	NULL
:	NULL
-	NULL
``	NULL
%	NULL
%	NULL
``	NULL
i	NULL
.	NULL

&	NULL
A	NULL
.	NULL

=-3	NULL
#	NULL
a	NULL
-	NULL
>	NULL
'	NULL
Lane:1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
c	NULL
Probe	NULL
:	NULL
CD11b	NULL
-90	NULL
to	NULL
+40	NULL
Extract	NULL
:	NULL
;	NULL
U937|	NULL
HeLa	NULL
|Sp1	NULL
Competitor	NULL
:	NULL
wt	NULL
m	NULL
woven	NULL
nf	NULL
»	NULL
7G	NULL
)	NULL
s	NULL
wo	NULL
#	NULL
A	NULL
--	NULL
>	NULL
-	NULL
.	NULL

‘	NULL
A*	NULL
-	NULL
>	NULL
]	NULL
Hee	NULL
PU	NULL
_-	NULL
}	NULL
-	NULL
ae	NULL
Lanes	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
d	NULL
CD1lb	NULL
wild	NULL
type	NULL
wt-78	NULL
bp	NULL
-78	NULL
bp	NULL
-49	NULL
-78	NULL
to	NULL
-49	NULL
#	NULL
k	NULL
CD11b	NULL
mutant	NULL
m-78	NULL
bp	NULL
-78	NULL
TGCTCACTGAGCCTCCGAGCTCTTCCTTTG	NULL
bp	NULL
-49	NULL
-78	NULL
to-	NULL
49	NULL
CD1lb	NULL
wild	NULL
type	NULL
wt-114	NULL
bp	NULL
-85	NULL
CCTGCCTGGTCTTCCGCCCAGGACTGCCCA	NULL
bp	NULL
-114	NULL
-114	NULL
to	NULL
-84	NULL
tissue	NULL
plasminogen	NULL
t-PA	NULL
AGAAACCCCGCCCACACCTCTGGCCCCACCCCTTCTTCA	NULL
activator	NULL
wild	NULL
type	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
analysis	NULL
(	NULL
EMSA	NULL
)	NULL
of	NULL
the	NULL
CD11b	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
region	NULL
.	NULL

Panel	NULL
a	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
TPA-induced	NULL
U937	NULL
cells	NULL
(	NULL
lanes	NULL
1-7	NULL
)	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
were	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
.	NULL

All	NULL
lanes	NULL
contain	NULL
bp	NULL
-90	NULL
to	NULL
bp	NULL
+40	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligos	NULL
(	NULL
panel	NULL
d	NULL
)	NULL
were	NULL
added	NULL
at	NULL
50-fold	NULL
molar	NULL
excess	NULL
over	NULL
probe	NULL
oligo	NULL
:	NULL
lanes	NULL
1	NULL
and	NULL
8	NULL
,	NULL
no	NULL
competitor	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
wild	NULL
type	NULL
bp	NULL
-78	NULL
oligo	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
mutant	NULL
bp	NULL
-78	NULL
oligo	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
wild	NULL
type	NULL
bp	NULL
-114	NULL
oligo	NULL
.	NULL

PU.1	NULL
refers	NULL
to	NULL
the	NULL
complex	NULL
formed	NULL
in	NULL
U937	NULL
cells	NULL
by	NULL
PU.1	NULL
binding	NULL
the	NULL
CD11b	NULL
promoter	NULL
at	NULL
bp	NULL
-20	NULL
.	NULL

In	NULL
lane	NULL
5	NULL
,	NULL
this	NULL
complex	NULL
is	NULL
competed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
bp	NULL
-26	NULL
to	NULL
+2	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
,	NULL
abbreviated	NULL
wt-PU	NULL
(	NULL
12	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
6	NULL
the	NULL
competitor	NULL
is	NULL
the	NULL
CD11b	NULL
bp	NULL
-90	NULL
to	NULL
+40	NULL
fragment	NULL
,	NULL
abbreviated	NULL
CD11b	NULL
.	NULL

In	NULL
lane	NULL
7	NULL
,	NULL
the	NULL
competitor	NULL
is	NULL
a	NULL
97-bp	NULL
fragment	NULL
of	NULL
the	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
promoter	NULL
,	NULL
abbreviated	NULL
t-PA	NULL
(	NULL
panel	NULL
d	NULL
)	NULL
.	NULL

A	NULL
and	NULL
A*	NULL
refer	NULL
to	NULL
complexes	NULL
specifically	NULL
bound	NULL
to	NULL
the	NULL
CD11b	NULL
wild	NULL
type	NULL
bp	NULL
-90	NULL
to	NULL
+40	NULL
probe	NULL
(	NULL
see	NULL
``	NULL
Results	NULL
``	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
achieve	NULL
adequate	NULL
separation	NULL
of	NULL
bands	NULL
A	NULL
and	NULL
A*	NULL
,	NULL
the	NULL
gel	NULL
was	NULL
electrophoresed	NULL
sufficiently	NULL
long	NULL
such	NULL
that	NULL
unbound	NULL
(	NULL
free	NULL
)	NULL
probe	NULL
was	NULL
run	NULL
off	NULL
the	NULL
bottom	NULL
;	NULL
similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
gel	NULL
runs	NULL
of	NULL
shorter	NULL
duration	NULL
,	NULL
in	NULL
which	NULL
the	NULL
free	NULL
probe	NULL
remained	NULL
on	NULL
the	NULL
gel	NULL
(	NULL
panel	NULL
c	NULL
)	NULL
.	NULL

Panel	NULL
b	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
TPA-induced	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
lanes	NULL
1-4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
were	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
.	NULL

Lanes	NULL
1-5	NULL
contain	NULL
bp	NULL
-78	NULL
to	NULL
bp	NULL
-49	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

In	NULL
lane	NULL
6	NULL
the	NULL
mutant	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
probe	NULL
was	NULL
used	NULL
,	NULL
and	NULL
in	NULL
lane	NULL
7	NULL
a	NULL
30-bp	NULL
oligonucleotide	NULL
from	NULL
bp	NULL
-114	NULL
to	NULL
bp	NULL
-85	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligos	NULL
(	NULL
panel	NULL
d	NULL
)	NULL
were	NULL
added	NULL
at	NULL
50-fold	NULL
molar	NULL
excess	NULL
over	NULL
probe	NULL
oligo	NULL
:	NULL
lanes	NULL
1	NULL
,	NULL
5-7	NULL
,	NULL
no	NULL
competitor	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
wild	NULL
type	NULL
bp	NULL
-78	NULL
oligo	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
mutant	NULL
bp	NULL
-78	NULL
oligo	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
wild	NULL
type	NULL
bp	NULL
-114	NULL
oligo	NULL
.	NULL

Panel	NULL
c	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
TPA-induced	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
were	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
.	NULL

Lane	NULL
5	NULL
contains	NULL
0.5	NULL
footprinting	NULL
units	NULL
of	NULL
affinity	NULL
purified	NULL
Sp1	NULL
protein	NULL
instead	NULL
of	NULL
nuclear	NULL
extract	NULL
.	NULL

All	NULL
lanes	NULL
contain	NULL
bp	NULL
-90	NULL
to	NULL
bp	NULL
+40	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

In	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
the	NULL
following	NULL
unlabeled	NULL
competitor	NULL
oligos	NULL
(	NULL
panel	NULL
d	NULL
)	NULL
were	NULL
added	NULL
at	NULL
50-fold	NULL
molar	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
Probe	NULL
:	NULL
bp	NULL
-90	NULL
to	NULL
+40	NULL
Extract	NULL
:	NULL
U937	NULL
Antibody	NULL
:	NULL
-	NULL
Sp1	NULL
pre	NULL
SA	NULL
%	NULL
a-	NULL
>	NULL
M	NULL
®	NULL
A	NULL
'	NULL
ﬁ	NULL
«	NULL
42s	NULL
``	NULL
an	NULL
wo	NULL
ad	NULL
#	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
CD11b	NULL
binding	NULL
activity	NULL
as	NULL
Sp1	NULL
.	NULL

10	NULL
ug	NULL
of	NULL
TPA-induced	NULL
U937	NULL
extract	NULL
were	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
containing	NULL
bp	NULL
-90	NULL
to	NULL
bp	NULL
+40	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
CD11b	NULL
promoter	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
antibody	NULL
to	NULL
Spl	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
preimmune	NULL
serum	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
EMSA	NULL
reaction	NULL
prior	NULL
to	NULL
incubation	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
.	NULL

A	NULL
and	NULL
A*	NULL
refer	NULL
to	NULL
complexes	NULL
specifically	NULL
bound	NULL
to	NULL
the	NULL
CD11b	NULL
wild	NULL
type	NULL
bp	NULL
-90	NULL
to	NULL
+40	NULL
probe	NULL
(	NULL
see	NULL
``	NULL
Results	NULL
``	NULL
)	NULL
.	NULL

S	NULL
refers	NULL
to	NULL
the	NULL
supershifted	NULL
band	NULL
in	NULL
lane	NULL
2	NULL
.	NULL

MA	NULL
A*	NULL
F	NULL
8s	NULL
sity	NULL
--	NULL
-62	NULL
aan	NULL
=	NULL
--	NULL
-68	NULL
tte	NULL
vam	NULL
wae	NULL
m	NULL
-_	NULL
.	NULL

7	NULL
)	NULL
,	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Methylation	NULL
interference	NULL
analysis	NULL
of	NULL
DNA	NULL
contact	NULL
points	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
A*	NULL
.	NULL

The	NULL
-78	NULL
to	NULL
-49	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
was	NULL
5	NULL
'	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y-*P	NULL
]	NULL
ATP	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
,	NULL
annealed	NULL
with	NULL
a	NULL
complementary	NULL
noncoding	NULL
oligonucleotide	NULL
,	NULL
and	NULL
methylated	NULL
by	NULL
treatment	NULL
with	NULL
limiting	NULL
quantities	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
.	NULL

2	NULL
ng	NULL
of	NULL
probe	NULL
were	NULL
incubated	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
U937	NULL
nuclear	NULL
extract	NULL
in	NULL
a	NULL
preparative	NULL
mobility	NULL
shift	NULL
assay	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Complexes	NULL
A	NULL
,	NULL
A	NULL
'	NULL
``	NULL
,	NULL
and	NULL
the	NULL
free	NULL
(	NULL
unbound	NULL
)	NULL
probe	NULL
were	NULL
isolated	NULL
,	NULL
subjected	NULL
to	NULL
piperidine-mediated	NULL
cleavage	NULL
of	NULL
methylated	NULL
G	NULL
residues	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
on	NULL
8	NULL
M	NULL
urea	NULL
,	NULL
15	NULL
%	NULL
polyacrylamide	NULL
(	NULL
19:1	NULL
)	NULL
gels	NULL
followed	NULL
by	NULL
autoradiography	NULL
at	NULL
-80	NULL
°C	NULL
with	NULL
intensifying	NULL
screens	NULL
.	NULL

Lane	NULL
1	NULL
(	NULL
M	NULL
)	NULL
,	NULL
methylated	NULL
DNA	NULL
oligonucleotide	NULL
probe	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
complex	NULL
A	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
complex	NULL
A*	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
free	NULL
(	NULL
unbound	NULL
probe	NULL
)	NULL
.	NULL

P	NULL
represents	NULL
the	NULL
uncleaved	NULL
oligonucleotide	NULL
,	NULL
and	NULL
numbers	NULL
on	NULL
the	NULL
right	NULL
of	NULL
the	NULL
figure	NULL
indicate	NULL
the	NULL
position	NULL
of	NULL
G	NULL
residues	NULL
relative	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
.	NULL

cells	NULL
,	NULL
where	NULL
the	NULL
CD11b	NULL
promoter	NULL
is	NULL
significantly	NULL
less	NULL
active	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
Sp1	NULL
site	NULL
decreased	NULL
the	NULL
low-level	NULL
CD11b	NULL
promoter	NULL
activity	NULL
10-fold	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
strong	NULL
effect	NULL
of	NULL
this	NULL
mutation	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
entire	NULL
412-bp	NULL
promoter	NULL
suggests	NULL
that	NULL
the	NULL
Sp1	NULL
site	NULL
is	NULL
essential	NULL
not	NULL
only	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
92-bp	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
but	NULL
that	NULL
there	NULL
are	NULL
no	NULL
other	NULL
factors	NULL
present	NULL
in	NULL
the	NULL
412-bp	NULL
promoter	NULL
which	NULL
can	NULL
compensate	NULL
for	NULL
the	NULL
loss	NULL
of	NULL
promoter	NULL
activity	NULL
following	NULL
mutation	NULL
of	NULL
the	NULL
Spl	NULL
site	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
Sp1	NULL
consensus	NULL
site	NULL
at	NULL
bp	NULL
-100	NULL
,	NULL
which	NULL
does	NULL
not	NULL
bind	NULL
Spl	NULL
in	NULL
EMSAs	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
lane	NULL
4	NULL
;	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
8235	NULL
%	NULL
Activity	NULL
%	NULL
Activity	NULL
RLU	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
8	NULL
8	NULL
e	NULL
&	NULL
a0	NULL
%	NULL
100	NULL
%	NULL
3	NULL
376,443	NULL
&	NULL
412	NULL
co11b	NULL
&	NULL
~	NULL
|spi-mutant	NULL
7	NULL
5.5	NULL
+/-	NULL
0.75	NULL
20,852	NULL
+/-	NULL
2823	NULL
-a12con1b	NULL
[	NULL
Z	NULL
S	NULL
|wild	NULL
type	NULL
4.1	NULL
+/-	NULL
0.95	NULL
15,595	NULL
+/-	NULL
3576	NULL
o	NULL
412	NULL
CD11b	NULL
AC	NULL
Sp1-mutant	NULL
0.4	NULL
+/-	NULL
0.1	NULL
1867	NULL
+/-	NULL
376	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
Spl	NULL
site	NULL
significantly	NULL
reduces	NULL
CD11b	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
412-bp	NULL
CD11b	NULL
promoter	NULL
or	NULL
the	NULL
promoter	NULL
carrying	NULL
a	NULL
2-bp	NULL
mutation	NULL
in	NULL
the	NULL
Spl	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
were	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
and	NULL
transiently	NULL
transfected	NULL
into	NULL
macrophage	NULL
(	NULL
TPA-induced	NULL
U937	NULL
)	NULL
or	NULL
cervical	NULL
carcinoma	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
duplicate	NULL
,	NULL
and	NULL
the	NULL
average	NULL
and	NULL
standard	NULL
error	NULL
relative	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
412-bp	NULL
promoter	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
100	NULL
%	NULL
activity	NULL
)	NULL
of	NULL
four	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Luciferase	NULL
activity	NULL
is	NULL
reported	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
,	NULL
and	NULL
results	NULL
are	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
a	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
plasmid	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Background	NULL
luciferase	NULL
activity	NULL
,	NULL
obtained	NULL
from	NULL
transfection	NULL
of	NULL
the	NULL
promoterless	NULL
pXP2	NULL
parent	NULL
plasmid	NULL
,	NULL
was	NULL
280	NULL
RLU	NULL
.	NULL

%	NULL
Activity	NULL
fold	NULL
induction	NULL
RLU	NULL
&	NULL
§00§	NULL
$	NULL
f	NULL
3	NULL
§	NULL
_s	NULL
_	NULL
8	NULL
8	NULL
°	NULL
412	NULL
CD1th	NULL
9,856	NULL
+/-379	NULL
wild	NULL
type	NULL
7,595	NULL
+/-	NULL
376	NULL
412	NULL
CD1th	NULL
Sp1-mutant	NULL
412	NULL
D	NULL
|	NULL
maype	NULL
6.07	NULL
65,789	NULL
+/-	NULL
782	NULL
+	NULL
pPacSp1	NULL
«	NULL
412	NULL
CD11b	NULL
1.3	NULL
10,206	NULL
+/-423	NULL
+	NULL
pPacSp1	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Spl	NULL
stimulates	NULL
transcription	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
at	NULL
the	NULL
-60	NULL
bp	NULL
site	NULL
in	NULL
transactivation	NULL
assays	NULL
.	NULL

Drosophila	NULL
Schneider	NULL
S2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
-412	NULL
CD11b-lucif-erase	NULL
reporter	NULL
,	NULL
the	NULL
Sp1	NULL
(	NULL
bp	NULL
-60	NULL
and	NULL
-61	NULL
)	NULL
mutant	NULL
reporter	NULL
,	NULL
or	NULL
the	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
reporters	NULL
cotransfected	NULL
with	NULL
the	NULL
pPacSpl	NULL
expression	NULL
construct	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
legend	NULL
to	NULL
the	NULL
left	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
14	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
figure	NULL
as	NULL
percent	NULL
of	NULL
the	NULL
activity	NULL
obtained	NULL
by	NULL
cotransfection	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
reporter	NULL
with	NULL
the	NULL
Spl	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
relative	NULL
light	NULL
units/nanogram	NULL
of	NULL
growth	NULL
hormone	NULL
activity	NULL
(	NULL
to	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
)	NULL
are	NULL
given	NULL
on	NULL
the	NULL
right	NULL
hand	NULL
side	NULL
of	NULL
the	NULL
figure	NULL
(	NULL
RLU	NULL
)	NULL
.	NULL

-Fold	NULL
induction	NULL
represents	NULL
the	NULL
RLU	NULL
of	NULL
wild	NULL
type	NULL
or	NULL
mutant	NULL
CD11b	NULL
reporter	NULL
plasmid	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cotransfected	NULL
Sp1	NULL
divided	NULL
by	NULL
that	NULL
obtained	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Spl	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
the	NULL
mean	NULL
and	NULL
standard	NULL
error	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

7	NULL
)	NULL
,	NULL
can	NULL
not	NULL
replace	NULL
the	NULL
function	NULL
of	NULL
the	NULL
Sp1-binding	NULL
site	NULL
at	NULL
bp	NULL
-60	NULL
.	NULL

To	NULL
demonstrate	NULL
directly	NULL
that	NULL
Sp1	NULL
can	NULL
bind	NULL
to	NULL
and	NULL
activate	NULL
the	NULL
CD11b	NULL
promoter	NULL
,	NULL
we	NULL
cotransfected	NULL
CD11b	NULL
reporter	NULL
constructs	NULL
with	NULL
a	NULL
Sp1	NULL
expression	NULL
vector	NULL
(	NULL
pPac§Sp1	NULL
)	NULL
into	NULL
Drosophila	NULL
Schneider	NULL
(	NULL
$	NULL
2	NULL
)	NULL
cells	NULL
,	NULL
which	NULL
,	NULL
unlike	NULL
most	NULL
mammalian	NULL
cells	NULL
,	NULL
lack	NULL
endogenous	NULL
Sp1	NULL
.	NULL

When	NULL
the	NULL
pPac§Spl	NULL
construct	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
-412-bp	NULL
CD11b	NULL
reporter	NULL
construct	NULL
,	NULL
luciferase	NULL
activity	NULL
increased	NULL
6-fold	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

No	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
was	NULL
seen	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
pPacSpl	NULL
construct	NULL
,	NULL
when	NULL
the	NULL
two-bp	NULL
mutation	NULL
at	NULL
bp	NULL
-60	NULL
and	NULL
-61	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
was	NULL
introduced	NULL
into	NULL
the	NULL
412-bp	NULL
CD11b	NULL
promoter	NULL
,	NULL
or	NULL
when	NULL
a	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
expression	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
CD11b	NULL
luciferase	NULL
reporter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
Sp1	NULL
protein	NULL
and	NULL
excess	NULL
over	NULL
probe	NULL
:	NULL
lane	NULL
3	NULL
,	NULL
wild	NULL
type	NULL
bp	NULL
-78	NULL
oligo	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
mutant	NULL
bp	NULL
-78	NULL
oligo	NULL
.	NULL

Panel	NULL
d	NULL
,	NULL
names	NULL
,	NULL
abbreviations	NULL
,	NULL
and	NULL
sequences	NULL
of	NULL
oligos	NULL
and	NULL
DNA	NULL
fragments	NULL
used	NULL
in	NULL
EMSAs	NULL
.	NULL

Nucleotides	NULL
altered	NULL
in	NULL
the	NULL
bp	NULL
-78	NULL
to	NULL
-49	NULL
mutant	NULL
oligonucleotide	NULL
are	NULL
marked	NULL
with	NULL
asterisks	NULL
,	NULL
and	NULL
the	NULL
core	NULL
binding	NULL
region	NULL
for	NULL
the	NULL
Sp1	NULL
transcription	NULL
factor	NULL
is	NULL
underlined	NULL
.	NULL

The	NULL
CD11b	NULL
sequences	NULL
in	NULL
the	NULL
-114	NULL
to	NULL
-85	NULL
region	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
noncoding	NULL
strand	NULL
so	NULL
as	NULL
to	NULL
facilitate	NULL
visual	NULL
comparison	NULL
with	NULL
the	NULL
CD11b	NULL
-60	NULL
site	NULL
as	NULL
well	NULL
as	NULL
the	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
site	NULL
.	NULL

8236	NULL
an	NULL
intact	NULL
Sp1l-binding	NULL
site	NULL
at	NULL
bp	NULL
60	NULL
and	NULL
61	NULL
were	NULL
specifically	NULL
necessary	NULL
for	NULL
an	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
.	NULL

These	NULL
observations	NULL
and	NULL
the	NULL
data	NULL
obtained	NULL
in	NULL
EMSAs	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
model	NULL
that	NULL
Sp1	NULL
binds	NULL
to	NULL
and	NULL
activates	NULL
the	NULL
CD11b	NULL
promoter	NULL
,	NULL
and	NULL
that	NULL
Sp1	NULL
binding	NULL
is	NULL
essential	NULL
for	NULL
CD11b	NULL
promoter	NULL
activity	NULL
.	NULL

Sp1	NULL
Binds	NULL
the	NULL
CD11b	NULL
Promoter	NULL
Selectively	NULL
in	NULL
Myeloid	NULL
Cells	NULL
in	NULL
Vivo-In	NULL
order	NULL
to	NULL
fully	NULL
characterize	NULL
the	NULL
Sp1-binding	NULL
site	NULL
,	NULL
we	NULL
performed	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
footprinting	NULL
assays	NULL
.	NULL

In	NULL
both	NULL
EMSAs	NULL
and	NULL
in	NULL
vitro	NULL
footprinting	NULL
assays	NULL
,	NULL
protein-DNA	NULL
interactions	NULL
occur	NULL
on	NULL
short	NULL
,	NULL
plasmid-derived	NULL
DNA	NULL
fragments	NULL
in	NULL
vitro	NULL
and	NULL
may	NULL
thus	NULL
not	NULL
accurately	NULL
reflect	NULL
binding	NULL
reactions	NULL
occurring	NULL
on	NULL
promoters	NULL
embedded	NULL
in	NULL
chromosomal	NULL
structures	NULL
in	NULL
vivo	NULL
.	NULL

For	NULL
example	NULL
,	NULL
in	NULL
vitro	NULL
the	NULL
muscle	NULL
creatine	NULL
kinase	NULL
promoter	NULL
binds	NULL
myoD	NULL
when	NULL
nuclear	NULL
extracts	NULL
from	NULL
either	NULL
myoblasts	NULL
or	NULL
myocytes	NULL
are	NULL
used	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
however	NULL
,	NULL
these	NULL
sites	NULL
are	NULL
only	NULL
bound	NULL
in	NULL
myocytes	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
vivo	NULL
footprinting	NULL
may	NULL
more	NULL
accurately	NULL
reflect	NULL
protein-DNA	NULL
binding	NULL
reactions	NULL
occurring	NULL
on	NULL
chromatin	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

We	NULL
therefore	NULL
compared	NULL
occupancy	NULL
of	NULL
the	NULL
Sp1	NULL
site	NULL
in	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
and	NULL
non-myeloid	NULL
(	NULL
HeLa	NULL
)	NULL
nuclear	NULL
extracts	NULL
or	NULL
in	NULL
intact	NULL
cells	NULL
using	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
footprinting	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
sequences	NULL
between	NULL
bp	NULL
-55	NULL
and	NULL
-86	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
and	NULL
bp	NULL
-52	NULL
and	NULL
-73	NULL
on	NULL
the	NULL
non-coding	NULL
strand	NULL
are	NULL
protected	NULL
from	NULL
DNase	NULL
I	NULL
digestion	NULL
when	NULL
incubated	NULL
with	NULL
either	NULL
U937	NULL
or	NULL
HeLa	NULL
cell	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
only	NULL
U937	NULL
cells	NULL
show	NULL
protection	NULL
from	NULL
dimethyl	NULL
sulfide	NULL
methylation	NULL
between	NULL
bp	NULL
-54	NULL
and	NULL
-70	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
a	NULL
and	NULL
b	NULL
,	NULL
lane	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

8¢	NULL
,	NULL
lane	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

9a	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
no	NULL
in	NULL
vivo	NULL
footprint	NULL
is	NULL
seen	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
Figs	NULL
.	NULL

8	NULL
and	NULL
9	NULL
)	NULL
,	NULL
in	NULL
which	NULL
the	NULL
pattern	NULL
generated	NULL
precisely	NULL
corresponds	NULL
to	NULL
that	NULL
produced	NULL
by	NULL
naked	NULL
genomic	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
a	NULL
and	NULL
b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

8¢	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
.	NULL

This	NULL
in	NULL
vivo	NULL
binding	NULL
activity	NULL
is	NULL
present	NULL
in	NULL
both	NULL
uninduced	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8a	NULL
,	NULL
lane	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

9a	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
U937	NULL
cells	NULL
induced	NULL
toward	NULL
monocytic	NULL
differentiation	NULL
with	NULL
TPA	NULL
(	NULL
Fig	NULL
.	NULL

8¢	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
myeloid-specific	NULL
in	NULL
vivo	NULL
binding	NULL
is	NULL
observed	NULL
in	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
(	NULL
Fig	NULL
.	NULL

8¢	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

8¢	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
the	NULL
binding	NULL
is	NULL
observed	NULL
in	NULL
normal	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
a	NULL
92-bp	NULL
CD11b	NULL
promoter	NULL
construct	NULL
directs	NULL
``	NULL
tissue-specific	NULL
``	NULL
expression	NULL
of	NULL
luciferase	NULL
constructs	NULL
in	NULL
cell	NULL
lines	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Examination	NULL
of	NULL
the	NULL
entire	NULL
-92	NULL
bp	NULL
region	NULL
on	NULL
the	NULL
non-coding	NULL
strand	NULL
demonstrated	NULL
only	NULL
one	NULL
additional	NULL
site	NULL
consistently	NULL
protected	NULL
from	NULL
in	NULL
vivo	NULL
meth-ylation	NULL
,	NULL
and	NULL
this	NULL
was	NULL
located	NULL
at	NULL
bp	NULL
-17	NULL
and	NULL
-19	NULL
,	NULL
adjacent	NULL
to	NULL
a	NULL
hypersensitive	NULL
site	NULL
located	NULL
at	NULL
bp	NULL
-16	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
b	NULL
and	NULL
c	NULL
)	NULL
.	NULL

This	NULL
region	NULL
corresponds	NULL
to	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
myeloid-specific	NULL
F	NULL
U	NULL
H	NULL
WB	NULL
wien	NULL
NOX	NULL
``	NULL
where	NULL
z	NULL
bp	NULL
-73	NULL
nlm	NULL
.	NULL

@	NULL
..	NULL
«	NULL
z	NULL
bp	NULL
-52	NULL
Lanes	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

In	NULL
vitro	NULL
footprinting	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

The	NULL
coding	NULL
strand	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
was	NULL
labeled	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
at	NULL
bp	NULL
+	NULL
106	NULL
and	NULL
subjected	NULL
to	NULL
DNase	NULL
I	NULL
digestion	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
incubated	NULL
with	NULL
80	NULL
ug	NULL
of	NULL
uninduced	NULL
U937	NULL
nuclear	NULL
extract	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
80	NULL
ug	NULL
of	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
extract	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
subsequently	NULL
subjected	NULL
to	NULL
DNase	NULL
I	NULL
digestion	NULL
.	NULL

The	NULL
noncoding	NULL
strand	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
was	NULL
labeled	NULL
at	NULL
the	NULL
EcoRI	NULL
site	NULL
at	NULL
bp	NULL
-264	NULL
and	NULL
subjected	NULL
to	NULL
DNase	NULL
I	NULL
digestion	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
incubated	NULL
with	NULL
80	NULL
ug	NULL
of	NULL
uninduced	NULL
U937	NULL
nuclear	NULL
extract	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
or	NULL
80	NULL
ug	NULL
of	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
extract	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
subsequently	NULL
subjected	NULL
to	NULL
DNase	NULL
I	NULL
digestion	NULL
.	NULL

Brackets	NULL
surround	NULL
sequences	NULL
protected	NULL
from	NULL
DNase	NULL
I	NULL
digestion	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
nuclear	NULL
extracts	NULL
.	NULL

Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
a	NULL
D	NULL
U	NULL
He	NULL
-	NULL
16	NULL
ie	NULL
i=	NULL
:	NULL
-	NULL
~*	NULL
-	NULL
-	NULL
-53	NULL
wam	NULL
-	NULL
-63	NULL
f	NULL
Q	NULL
-	NULL
O75	NULL
k	NULL
-	NULL
as	NULL
--	NULL
82	NULL
«	NULL
e	NULL
wit	NULL
__	NULL
92	NULL
1	NULL
2	NULL
3	NULL
b	NULL
D	NULL
UQ	NULL
He	NULL
4	NULL
bp	NULL
-	NULL
53	NULL
bp—57|	NULL
:	NULL
bp	NULL
-	NULL
66	NULL
g	NULL
bp	NULL
-	NULL
76	NULL
-	NULL
g.	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
C	NULL
in	NULL
D	NULL
U	NULL
M	NULL
THe	NULL
¥	NULL
-	NULL
-7	NULL
wa	NULL
-	NULL
-17	NULL
ee	NULL
.N	NULL
‘	NULL
—	NULL
-53	NULL
``	NULL
'	NULL
``	NULL
-'.—	NULL
-66	NULL
STERBE	NULL
_.	NULL
;	NULL
wam	NULL
sis	NULL
==	NULL
mm	NULL
me	NULL
__	NULL
.	NULL

93	NULL
wo	NULL
mes	NULL
w	NULL
»	NULL
-	NULL
-100	NULL
«	NULL
«	NULL
<	NULL
-	NULL
sane	NULL
(	NULL
ip	NULL
mas	NULL
we	NULL
mee	NULL
ae	NULL
-	NULL
-110	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
on	NULL
the	NULL
non-coding	NULL
strand	NULL
.	NULL

Panels	NULL
a	NULL
and	NULL
b	NULL
Naked	NULL
genomic	NULL
DNA	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
intact	NULL
uninduced	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
were	NULL
exposed	NULL
to	NULL
dimethyl	NULL
sulfide	NULL
and	NULL
in	NULL
vivo	NULL
footprints	NULL
visualized	NULL
by	NULL
the	NULL
ligation-mediated-PCR	NULL
method	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
panel	NULL
a	NULL
,	NULL
the	NULL
numbers	NULL
in	NULL
the	NULL
right	NULL
margin	NULL
indicate	NULL
the	NULL
position	NULL
relative	NULL
to	NULL
the	NULL
CD11b	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

Panel	NULL
b	NULL
represents	NULL
an	NULL
enlargement	NULL
of	NULL
the	NULL
-76	NULL
to	NULL
-53	NULL
region	NULL
shown	NULL
in	NULL
panel	NULL
a	NULL
.	NULL

In	NULL
panel	NULL
b	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
is	NULL
given	NULL
in	NULL
the	NULL
right	NULL
margin	NULL
.	NULL

A	NULL
bracket	NULL
surrounds	NULL
protected	NULL
cytidine	NULL
residues	NULL
.	NULL

Lane	NULL
2	NULL
is	NULL
underloaded	NULL
compared	NULL
to	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
;	NULL
however	NULL
,	NULL
densitometer	NULL
scanning	NULL
demonstrated	NULL
that	NULL
in	NULL
lane	NULL
2	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
triplet	NULL
cytidine	NULL
residues	NULL
at	NULL
bp	NULL
-59	NULL
to	NULL
-61	NULL
,	NULL
in	NULL
the	NULL
center	NULL
of	NULL
the	NULL
Sp1-binding	NULL
site	NULL
,	NULL
decreased	NULL
2.6-fold	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
lane	NULL
3	NULL
,	NULL
whereas	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
doublet	NULL
near	NULL
the	NULL
top	NULL
of	NULL
the	NULL
gel	NULL
(	NULL
bp	NULL
-43	NULL
and	NULL
-45	NULL
)	NULL
decreased	NULL
only	NULL
1.3-fold	NULL
.	NULL

Panel	NULL
c	NULL
,	NULL
in	NULL
vivo	NULL
footprints	NULL
were	NULL
performed	NULL
as	NULL
in	NULL
panels	NULL
a	NULL
and	NULL
b	NULL
,	NULL
except	NULL
DNA	NULL
from	NULL
the	NULL
following	NULL
cells	NULL
were	NULL
used	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
naked	NULL
genomic	NULL
DNA	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
TPA-induced	NULL
U937	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
human	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
;	NULL
lame	NULL
4	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
HeLa	NULL
cells	NULL
.	NULL

transcription	NULL
factor	NULL
PU.1	NULL
,	NULL
which	NULL
we	NULL
have	NULL
observed	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
-19	NULL
bp	NULL
region	NULL
in	NULL
vitro	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
opposite	NULL
(	NULL
coding	NULL
)	NULL
strand	NULL
revealed	NULL
a	NULL
relative	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
a	NULL
U	NULL
U	NULL
He	NULL
-	NULL
16	NULL
-	NULL
-35	NULL
-	NULL
43	NULL
se	NULL
-	NULL
~53	NULL
a	NULL
-	NULL
8	NULL
-	NULL
-s	NULL
8	NULL
@	NULL
-	NULL
-83	NULL
bad	NULL
ws	NULL
-	NULL
-100	NULL
1	NULL
2	NULL
3	NULL
w	NULL
H	NULL
U	NULL
He	NULL
at	NULL
ue	NULL
t-	NULL
~*	NULL
-	NULL
_	NULL
-	NULL
19	NULL
5	NULL
--	NULL
33	NULL
-	NULL
o	NULL
=	NULL
#	NULL
i	NULL
:	NULL
1	NULL
%	NULL
3	NULL
c	NULL
HL60	NULL
U937	NULL
HeLa	NULL
wan	NULL
me	NULL
but	NULL
-	NULL
>	NULL
q	NULL
#	NULL
-	NULL
-16	NULL
``	NULL
``	NULL
Ce	NULL
-	NULL
~19	NULL
nual	NULL
NES	NULL
b	NULL
-	NULL
-22	NULL
A	NULL
“	NULL
!	NULL

g	NULL
C*	NULL
``	NULL
,	NULL
#	NULL
-	NULL
#	NULL
1	NULL
2	NULL
3	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
on	NULL
the	NULL
non-coding	NULL
strand	NULL
at	NULL
the	NULL
bp	NULL
-20	NULL
PU.1	NULL
site	NULL
.	NULL

Panel	NULL
a	NULL
,	NULL
in	NULL
vivo	NULL
footprinting	NULL
was	NULL
performed	NULL
to	NULL
scan	NULL
the	NULL
entire	NULL
CD11b	NULL
promoter	NULL
between	NULL
bp	NULL
-16	NULL
and	NULL
-117	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
uninduced	NULL
U937	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
HeLa	NULL
cells	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
represent	NULL
the	NULL
same	NULL
reaction	NULL
;	NULL
lane	NULL
2	NULL
contains	NULL
one-fourth	NULL
of	NULL
the	NULL
amount	NULL
loaded	NULL
in	NULL
lane	NULL
1	NULL
.	NULL

Panels	NULL
b	NULL
and	NULL
¢	NULL
,	NULL
in	NULL
vivo	NULL
footprinting	NULL
was	NULL
performed	NULL
to	NULL
scan	NULL
the	NULL
region	NULL
from	NULL
-43	NULL
to	NULL
beyond	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
uninduced	NULL
U937	NULL
cells	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
HeLa	NULL
cells	NULL
.	NULL

Panel	NULL
c	NULL
represents	NULL
an	NULL
enlarged	NULL
detail	NULL
of	NULL
panel	NULL
b.	NULL
reversal	NULL
of	NULL
the	NULL
intensities	NULL
of	NULL
the	NULL
bands	NULL
at	NULL
bp	NULL
-68	NULL
and	NULL
-70	NULL
,	NULL
which	NULL
lie	NULL
just	NULL
5	NULL
of	NULL
the	NULL
``	NULL
core	NULL
``	NULL
Sp1	NULL
binding	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

As	NULL
the	NULL
PU.1-binding	NULL
site	NULL
at	NULL
bp	NULL
-20	NULL
does	NULL
not	NULL
contain	NULL
any	NULL
guanosine	NULL
residues	NULL
on	NULL
this	NULL
strand	NULL
,	NULL
no	NULL
protection	NULL
was	NULL
observed	NULL
.	NULL

8237	NULL
a	NULL
U	NULL
He	NULL
==	NULL
«	NULL
sk	NULL
--	NULL
-112	NULL
m	NULL
-	NULL
-9s	NULL
pag	NULL
--	NULL
70	NULL
--	NULL
G3	NULL
§	NULL
-	NULL
49	NULL
w	NULL
sam	NULL
=	NULL
--	NULL
~37	NULL
woe	NULL
sae	NULL
--	NULL
~30	NULL
woe	NULL
eme	NULL
.	NULL

--	NULL
-9	NULL
wash	NULL
ease	NULL
.	NULL

--	NULL
+2	NULL
1	NULL
2	NULL
b	NULL
U937	NULL
Hela	NULL
-	NULL
#	NULL
*	NULL
-112	NULL
--	NULL
-98	NULL
o	NULL
e	NULL
Z	NULL
;	NULL
-	NULL
-70	NULL
1	NULL
2	NULL
FiG	NULL
.	NULL

10	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
.	NULL

Panels	NULL
a	NULL
and	NULL
b	NULL
,	NULL
in	NULL
vivo	NULL
footprinting	NULL
was	NULL
performed	NULL
to	NULL
scan	NULL
the	NULL
region	NULL
between	NULL
bp	NULL
+2	NULL
and	NULL
-123	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
uninduced	NULL
U937	NULL
cells	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
HeLa	NULL
cells	NULL
.	NULL

Panel	NULL
b	NULL
represents	NULL
an	NULL
enlarged	NULL
detail	NULL
of	NULL
panel	NULL
a	NULL
.	NULL

The	NULL
arrows	NULL
point	NULL
to	NULL
the	NULL
residues	NULL
centered	NULL
around	NULL
bp	NULL
-112	NULL
and	NULL
at	NULL
bp	NULL
-70	NULL
protected	NULL
in	NULL
U937	NULL
cells	NULL
and	NULL
to	NULL
the	NULL
residue	NULL
at	NULL
bp	NULL
-68	NULL
which	NULL
is	NULL
hypersensitive	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

A	NULL
second	NULL
protected	NULL
area	NULL
was	NULL
detected	NULL
corresponding	NULL
to	NULL
the	NULL
3	NULL
G	NULL
residues	NULL
at	NULL
bp	NULL
-111	NULL
to	NULL
-113	NULL
;	NULL
no	NULL
protection	NULL
was	NULL
observed	NULL
in	NULL
this	NULL
region	NULL
on	NULL
the	NULL
non-coding	NULL
strand	NULL
(	NULL
Fig	NULL
.	NULL

9a	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
whereas	NULL
the	NULL
Spl	NULL
site	NULL
is	NULL
bound	NULL
in	NULL
vitro	NULL
by	NULL
nuclear	NULL
extracts	NULL
from	NULL
both	NULL
CD11b	NULL
expressing	NULL
U937	NULL
and	NULL
non-expressing	NULL
HeLa	NULL
cells	NULL
,	NULL
in	NULL
vivo	NULL
only	NULL
CD11b-expressing	NULL
U937	NULL
cells	NULL
and	NULL
monocytes	NULL
show	NULL
Spl	NULL
binding	NULL
;	NULL
protection	NULL
and/or	NULL
hypersensitive	NULL
sites	NULL
were	NULL
also	NULL
observed	NULL
at	NULL
the	NULL
PU.1-binding	NULL
site	NULL
at	NULL
bp	NULL
-20	NULL
and	NULL
at	NULL
an	NULL
as	NULL
yet	NULL
uncharacterized	NULL
site	NULL
at	NULL
bp	NULL
-112	NULL
.	NULL

A	NULL
summary	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
binding	NULL
data	NULL
is	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

11	NULL
.	NULL

DISCUSSION	NULL
Although	NULL
Sp1	NULL
is	NULL
universally	NULL
expressed	NULL
and	NULL
has	NULL
often	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
TATA-less	NULL
,	NULL
``	NULL
housekeeping	NULL
``	NULL
promoters	NULL
(	NULL
26	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
,	NULL
recent	NULL
evidence	NULL
suggests	NULL
that	NULL
Spl	NULL
expression	NULL
(	NULL
31	NULL
)	NULL
,	NULL
binding	NULL
affinity	NULL
(	NULL
32	NULL
)	NULL
,	NULL
and	NULL
post-translational	NULL
modifications	NULL
(	NULL
28	NULL
,	NULL
33	NULL
)	NULL
may	NULL
be	NULL
modulated	NULL
so	NULL
as	NULL
to	NULL
confer	NULL
tissue-specific	NULL
and	NULL
developmental	NULL
regulation	NULL
(	NULL
34	NULL
)	NULL
on	NULL
target	NULL
genes	NULL
.	NULL

Moreover	NULL
,	NULL
although	NULL
Spl	NULL
is	NULL
ubiquitously	NULL
expressed	NULL
,	NULL
levels	NULL
of	NULL
Sp1	NULL
expression	NULL
vary	NULL
greatly	NULL
among	NULL
tissues	NULL
;	NULL
developing	NULL
hematopoietic	NULL
cells	NULL
contain	NULL
among	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
Spl	NULL
mRNA	NULL
and	NULL
protein	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Spl	NULL
is	NULL
phosphorylated	NULL
and	NULL
differentially	NULL
glycosylated	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
,	NULL
allowing	NULL
additional	NULL
modulation	NULL
of	NULL
activity	NULL
(	NULL
28	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
CD11b	NULL
pro	NULL
8238	NULL
``	NULL
ppy.i	NULL
``	NULL
¥	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
``	NULL
Spi	NULL
``	NULL
¥	NULL
[	NULL
~-	NULL
TTGAAAGTTTGGGTCAGGAAGCTGGGGSAGGAAGGGTGGGCAGGCTGTGGGCAGTCCTGGGCGGAAGACCAGGCAGGGCTA	NULL
-160	NULL
I	NULL
I	NULL
1	NULL
AACTTTCAAACCCAGTCCTTCGACCCCTCCTTCCCACCCGTCCGACACCCGTCAGGACCCGCCTTCTGGTCCGTCCCGAT	NULL
Sp1	NULL
``	NULL
GATA	NULL
``	NULL
Y	NULL
Y	NULL
~-	NULL
Copii	NULL
0000	NULL
|	NULL
0	NULL
I	NULL
o	NULL
TGTGCTCACTGAGCCTCEGCCCTCTTCCTTTGAATCTCIGATAGACTTCTGCCTCCTACTTCTCCTTTTCTGCCCTTCTT	NULL
-80	NULL
Lt	NULL
.	NULL
'	NULL

.	NULL

I	NULL
I	NULL
I	NULL
ACACGAGTGACTCGGAGGCGGGAGAAGGAAACTTAGAGACTATCTGAAGACGGAGCATGAAGAGGAAAAGACGGGAAGAA	NULL
0	NULL
10	NULL
000	NULL
°	NULL
*	NULL
|	NULL
|	NULL
top	NULL
__|	NULL
A	NULL
PU.1	NULL
TGCTTTGGTGGCTTCCTTGTGGTTCCTCAGTGGTGCCTGCAACCCCTGGTTCACCTCCTTCCAGGTTCTGSCTCCTTCCA	NULL
+1	NULL
+81	NULL
-	NULL
GCCATGGGCTCTCAGAGTCCTTCTGTTAACAG	NULL
qtgcatgqqg	NULL
...	NULL
intron	NULL
1	NULL
--	NULL
>	NULL
Mo	NULL
A	NULL
L	NULL
R	NULL
V	NULL
L	NULL
L	NULL
L	NULL
T	NULL
A	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
1	NULL
ACGAAACCACCGAAGGAACACCAAGGAGTCACCACGGACGTTGGGGACCAAGTGGAGGAAGGTCCAAGACCGAGGAAGGT	NULL
Strong	NULL
protection	NULL
in	NULL
vivo	NULL
Weak	NULL
protection	NULL
in	NULL
vivo	NULL
Hypersensitivity	NULL
in	NULL
vivo	NULL
Contacts	NULL
detected	NULL
by	NULL
methylation	NULL
interference	NULL
in	NULL
vitro	NULL
[	NULL
~-1	NULL
DNase	NULL
I	NULL
Protection	NULL
in	NULL
vitro	NULL
_	NULL
Mutation	NULL
eliminates	NULL
binding	NULL
in	NULL
gel	NULL
mobility	NULL
shift	NULL
in	NULL
vitro	NULL
Mutation	NULL
eliminates	NULL
binding	NULL
=	NULL
in	NULL
gel	NULL
mobility	NULL
shift	NULL
in	NULL
vitro	NULL
and	NULL
decreases	NULL
function	NULL
in	NULL
transfection	NULL
assays	NULL
*	NULL
am	NULL
©	NULL
<	NULL
-	NULL
>	NULL
Fig	NULL
.	NULL

11	NULL
.	NULL

Summary	NULL
of	NULL
in	NULL
vitro	NULL
EMSA	NULL
and	NULL
footprinting	NULL
,	NULL
methylation	NULL
interference	NULL
,	NULL
and	NULL
in	NULL
vivo	NULL
footprinting	NULL
data	NULL
.	NULL

The	NULL
CD11b	NULL
promoter	NULL
sequence	NULL
(	NULL
11	NULL
)	NULL
on	NULL
both	NULL
coding	NULL
and	NULL
noncoding	NULL
strands	NULL
is	NULL
represented	NULL
from	NULL
bp	NULL
-160	NULL
to	NULL
bp	NULL
+80	NULL
,	NULL
and	NULL
from	NULL
bp	NULL
+81	NULL
to	NULL
bp	NULL
+122	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
only	NULL
;	NULL
bp	NULL
+1	NULL
to	NULL
+83	NULL
represents	NULL
the	NULL
5'-untranslated	NULL
region	NULL
,	NULL
and	NULL
bp	NULL
+84	NULL
to	NULL
bp	NULL
+112	NULL
(	NULL
in	NULL
italics	NULL
)	NULL
encodes	NULL
the	NULL
first	NULL
10	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
leader	NULL
sequence	NULL
(	NULL
presented	NULL
in	NULL
one-letter	NULL
code	NULL
below	NULL
the	NULL
DNA	NULL
sequence	NULL
)	NULL
;	NULL
bp	NULL
+113	NULL
to	NULL
+122	NULL
represents	NULL
the	NULL
first	NULL
10	NULL
bases	NULL
of	NULL
the	NULL
first	NULL
intron	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Vertical	NULL
bars	NULL
between	NULL
strands	NULL
(	NULL
|	NULL
)	NULL
denote	NULL
every	NULL
10	NULL
bases	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
the	NULL
potential	NULL
sites	NULL
for	NULL
DNA	NULL
binding	NULL
factors	NULL
.	NULL

The	NULL
``	NULL
consensus	NULL
``	NULL
sequences	NULL
GAGGAA	NULL
at	NULL
bp	NULL
-130	NULL
,	NULL
GGGCGG	NULL
at	NULL
bp	NULL
-100	NULL
,	NULL
and	NULL
TGATAG	NULL
at	NULL
bp	NULL
-40	NULL
,	NULL
representing	NULL
potential	NULL
PU.1	NULL
,	NULL
Spl	NULL
,	NULL
and	NULL
GATA	NULL
factor-binding	NULL
sites	NULL
,	NULL
are	NULL
underlined	NULL
and	NULL
labeled	NULL
in	NULL
quotation	NULL
marks	NULL
;	NULL
these	NULL
sites	NULL
do	NULL
not	NULL
bind	NULL
their	NULL
respective	NULL
factors	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
and	NULL
mutations	NULL
in	NULL
these	NULL
sites	NULL
do	NULL
not	NULL
significantly	NULL
affect	NULL
CD11b	NULL
promoter	NULL
activity	NULL
(	NULL
11	NULL
,	NULL
12	NULL
,	NULL
this	NULL
manuscript	NULL
)	NULL
.	NULL

The	NULL
symbols	NULL
used	NULL
to	NULL
denote	NULL
DNA	NULL
binding	NULL
results	NULL
are	NULL
presented	NULL
in	NULL
the	NULL
inset	NULL
and	NULL
represent	NULL
combined	NULL
data	NULL
from	NULL
Ref	NULL
.	NULL

12	NULL
and	NULL
this	NULL
manuscript	NULL
.	NULL

moter	NULL
,	NULL
like	NULL
the	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
promoter	NULL
and	NULL
other	NULL
promoters	NULL
regulated	NULL
by	NULL
the	NULL
Spl	NULL
transcription	NULL
factor	NULL
,	NULL
does	NULL
not	NULL
contain	NULL
a	NULL
TATA	NULL
box	NULL
(	NULL
11	NULL
,	NULL
18	NULL
,	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
unlike	NULL
certain	NULL
other	NULL
TAT	NULL
housekeeping	NULL
promoters	NULL
,	NULL
the	NULL
CD11b	NULL
promoter	NULL
is	NULL
highly	NULL
regulated	NULL
both	NULL
developmentally	NULL
and	NULL
in	NULL
a	NULL
tissue-specific	NULL
manner	NULL
(	NULL
11	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
an	NULL
Spl	NULL
site	NULL
at	NULL
bp	NULL
-60	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
is	NULL
essential	NULL
for	NULL
promoter	NULL
activity	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
the	NULL
sequence	NULL
5¢-CCGCCC-3	NULL
'	NULL
,	NULL
which	NULL
occurs	NULL
twice	NULL
in	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
at	NULL
bp	NULL
-60	NULL
and	NULL
bp	NULL
-100	NULL
)	NULL
,	NULL
only	NULL
binds	NULL
Spl	NULL
at	NULL
bp	NULL
-60	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
implicates	NULL
additional	NULL
base	NULL
pairs	NULL
outside	NULL
the	NULL
CCCGCC	NULL
consensus	NULL
in	NULL
contacting	NULL
Sp1	NULL
.	NULL

These	NULL
are	NULL
not	NULL
shared	NULL
by	NULL
the	NULL
site	NULL
around	NULL
bp	NULL
-100	NULL
(	NULL
Figs	NULL
.	NULL

2d	NULL
and	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
and	NULL
may	NULL
thus	NULL
be	NULL
essential	NULL
for	NULL
Spl	NULL
binding	NULL
.	NULL

Although	NULL
this	NULL
Sp1	NULL
site	NULL
is	NULL
bound	NULL
in	NULL
vitro	NULL
by	NULL
nuclear	NULL
extracts	NULL
from	NULL
either	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
or	NULL
non-myeloid	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
,	NULL
in	NULL
vivo	NULL
the	NULL
Spl	NULL
site	NULL
is	NULL
only	NULL
occupied	NULL
in	NULL
CD11b-expressing	NULL
myeloid	NULL
cells	NULL
.	NULL

Chromatin	NULL
structure	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
such	NULL
a	NULL
mechanism	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
the	NULL
Spl	NULL
site	NULL
in	NULL
the	NULL
CD11b	NULL
promoter	NULL
may	NULL
be	NULL
inaccessible	NULL
in	NULL
non-myeloid	NULL
cells	NULL
;	NULL
in	NULL
myeloid	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
binding	NULL
of	NULL
tissue-specific	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
PU.1	NULL
,	NULL
may	NULL
render	NULL
the	NULL
site	NULL
accessible	NULL
to	NULL
Sp1	NULL
binding	NULL
.	NULL

Rigaud	NULL
et	NULL
al	NULL
.	NULL

(	NULL
35	NULL
)	NULL
have	NULL
suggested	NULL
a	NULL
hit-and-run	NULL
mechanism	NULL
of	NULL
transcriptional	NULL
activation	NULL
,	NULL
whereby	NULL
chromatin	NULL
structure	NULL
is	NULL
altered	NULL
by	NULL
the	NULL
transient	NULL
binding	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
.	NULL

This	NULL
factor	NULL
rapidly	NULL
dissociates	NULL
from	NULL
the	NULL
DNA	NULL
,	NULL
leaving	NULL
the	NULL
site	NULL
accessible	NULL
for	NULL
a	NULL
second	NULL
binding	NULL
factor	NULL
.	NULL

In	NULL
the	NULL
CD11b	NULL
promoter	NULL
,	NULL
chromatin	NULL
structure	NULL
at	NULL
the	NULL
Spl	NULL
site	NULL
may	NULL
be	NULL
altered	NULL
by	NULL
transient	NULL
or	NULL
stable	NULL
binding	NULL
of	NULL
a	NULL
myeloid-specific	NULL
factor	NULL
.	NULL

After	NULL
binding	NULL
of	NULL
this	NULL
factor	NULL
,	NULL
the	NULL
site	NULL
becomes	NULL
accessible	NULL
to	NULL
Sp1	NULL
in	NULL
myeloid	NULL
(	NULL
U937	NULL
)	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
model	NULL
(	NULL
Fig	NULL
.	NULL

12	NULL
)	NULL
,	NULL
HeLa	NULL
cells	NULL
lack	NULL
the	NULL
myeloid-specific	NULL
binding	NULL
activity	NULL
,	NULL
the	NULL
chromatin	NULL
structure	NULL
in	NULL
these	NULL
cells	NULL
remains	NULL
unaltered	NULL
,	NULL
and	NULL
the	NULL
binding	NULL
site	NULL
is	NULL
inaccessible	NULL
to	NULL
Spl	NULL
.	NULL

A	NULL
leading	NULL
candidate	NULL
for	NULL
this	NULL
myeloid-specific	NULL
activity	NULL
is	NULL
PU.1	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
and	NULL
activates	NULL
the	NULL
CD11b	NULL
promoter	NULL
through	NULL
an	NULL
adjacent	NULL
site	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
binds	NULL
to	NULL
that	NULL
site	NULL
in	NULL
vivo	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
Spl	NULL
may	NULL
interact	NULL
with	NULL
additional	NULL
,	NULL
lineage-specific	NULL
,	NULL
non-DNA-binding	NULL
proteins	NULL
to	NULL
confer	NULL
myeloid-specific	NULL
binding	NULL
,	NULL
or	NULL
the	NULL
protein	NULL
may	NULL
be	NULL
specifically	NULL
modified	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
found	NULL
no	NULL
experimental	NULL
evidence	NULL
to	NULL
support	NULL
this	NULL
latter	NULL
possibility	NULL
.	NULL

We	NULL
have	NULL
observed	NULL
no	NULL
differences	NULL
in	NULL
protein-DNA	NULL
complexes	NULL
on	NULL
EMSAs	NULL
or	NULL
Southwestern	NULL
blots	NULL
,	NULL
or	NULL
phosphorylation	NULL
of	NULL
Spl	NULL
,	NULL
comparing	NULL
uninduced	NULL
and	NULL
differentiated	NULL
U937	NULL
and	NULL
HL-60	NULL
and	NULL
HeLa	NULL
nuclear	NULL
extracts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
Darrow	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
have	NULL
implicated	NULL
Spl	NULL
in	NULL
the	NULL
retinoic	NULL
acid-induced	NULL
expression	NULL
of	NULL
the	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
gene	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
myeloid	NULL
surface	NULL
antigen	NULL
CD11b	NULL
,	NULL
like	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
,	NULL
is	NULL
induced	NULL
by	NULL
retinoic	NULL
acid	NULL
,	NULL
we	NULL
see	NULL
no	NULL
change	NULL
in	NULL
Spl	NULL
binding	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
following	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
induced	NULL
with	NULL
either	NULL
retinoic	NULL
acid	NULL
or	NULL
TPA	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
Sp1	NULL
site	NULL
does	NULL
not	NULL
abrogate	NULL
either	NULL
retinoic	NULL
acid	NULL
Sp1	NULL
Is	NULL
Essential	NULL
for	NULL
CD11b	NULL
Promoter	NULL
Activity	NULL
a.	NULL
CD11b	NULL
LP	NULL
ss	NULL
J/PUJ	NULL
b.	NULL
CD11b	NULL
PV.1	NULL
U	NULL
c.	NULL
CD11b	NULL
Pu.1	NULL
>	NULL
AF	NULL
L_	NULL
J/	NULL
Sp1	NULL
a.	NULL
cbiib	NULL
__	NULL
SP1	NULL
PUA	NULL
Fic	NULL
.	NULL

12	NULL
.	NULL

Model	NULL
of	NULL
mechanism	NULL
of	NULL
myeloid-specific	NULL
binding	NULL
of	NULL
Spl	NULL
to	NULL
the	NULL
CD11b	NULL
promoter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PU.1	NULL
.	NULL

Panel	NULL
a	NULL
,	NULL
we	NULL
hypothesize	NULL
that	NULL
prior	NULL
to	NULL
commitment	NULL
of	NULL
stem	NULL
cells	NULL
to	NULL
myeloid	NULL
progenitors	NULL
,	NULL
neither	NULL
Spl	NULL
nor	NULL
PU.1	NULL
bind	NULL
to	NULL
the	NULL
CD11b	NULL
promoter	NULL
,	NULL
and	NULL
activity	NULL
is	NULL
undetectable	NULL
(	NULL
small	NULL
arrow	NULL
)	NULL
.	NULL

Panel	NULL
b	NULL
,	NULL
once	NULL
cells	NULL
become	NULL
committed	NULL
to	NULL
myeloid	NULL
progenitors	NULL
,	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
promoter	NULL
and	NULL
transcription	NULL
becomes	NULL
detectable	NULL
,	NULL
although	NULL
at	NULL
low	NULL
level	NULL
.	NULL

Panel	NULL
c	NULL
,	NULL
PU.1	NULL
induces	NULL
a	NULL
change	NULL
in	NULL
chromatin	NULL
structure	NULL
,	NULL
so	NULL
that	NULL
(	NULL
panel	NULL
d	NULL
)	NULL
Spl	NULL
can	NULL
now	NULL
bind	NULL
to	NULL
the	NULL
promoter	NULL
and	NULL
higher	NULL
level	NULL
activity	NULL
is	NULL
observed	NULL
.	NULL

Steps	NULL
a-d	NULL
occur	NULL
at	NULL
the	NULL
promyelocytic	NULL
(	NULL
HL-60	NULL
)	NULL
or	NULL
promonocytic	NULL
(	NULL
U937	NULL
)	NULL
stage	NULL
;	NULL
further	NULL
increases	NULL
of	NULL
CD11b	NULL
promoter	NULL
activity	NULL
seen	NULL
with	NULL
monocytic	NULL
or	NULL
neutrophilic	NULL
differentiation	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
proceeds	NULL
via	NULL
additional	NULL
mecha-nisms	NULL
,	NULL
since	NULL
Sp1	NULL
and	NULL
PU.1	NULL
DNA	NULL
binding	NULL
do	NULL
not	NULL
increase	NULL
with	NULL
myeloid	NULL
differentiation	NULL
(	NULL
12	NULL
;	NULL
Fig	NULL
.	NULL

8	NULL
;	NULL
R.	NULL
J.	NULL
Scheibe	NULL
,	NULL
H.	NULL
L.	NULL
Pahl	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

or	NULL
TPA-induced	NULL
up-regulation	NULL
of	NULL
CD11b	NULL
promoter	NULL
activity	NULL
following	NULL
transient	NULL
transfection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
Sp1	NULL
does	NULL
not	NULL
mediate	NULL
the	NULL
increase	NULL
in	NULL
CD11b	NULL
expression	NULL
and	NULL
transcription	NULL
rate	NULL
observed	NULL
after	NULL
monocytic	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
the	NULL
future	NULL
,	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
see	NULL
whether	NULL
potential	NULL
Spl-binding	NULL
sites	NULL
in	NULL
other	NULL
myeloid-specific	NULL
promoters	NULL
,	NULL
such	NULL
as	NULL
CD13	NULL
(	NULL
36	NULL
)	NULL
and	NULL
cathepsin	NULL
G	NULL
(	NULL
37	NULL
)	NULL
,	NULL
also	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
regulating	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

If	NULL
so	NULL
,	NULL
and	NULL
if	NULL
these	NULL
Spl	NULL
sites	NULL
are	NULL
also	NULL
bound	NULL
specifically	NULL
in	NULL
myeloid	NULL
cells	NULL
in	NULL
vivo	NULL
,	NULL
a	NULL
8239	NULL
general	NULL
mechanism	NULL
by	NULL
which	NULL
Spl	NULL
binds	NULL
selectively	NULL
in	NULL
certain	NULL
tissues	NULL
,	NULL
or	NULL
,	NULL
conversely	NULL
,	NULL
is	NULL
prevented	NULL
from	NULL
binding	NULL
in	NULL
other	NULL
tissues	NULL
,	NULL
may	NULL
be	NULL
derived	NULL
.	NULL

More	NULL
generally	NULL
,	NULL
a	NULL
hypothesis	NULL
may	NULL
be	NULL
derived	NULL
how	NULL
universally	NULL
expressed	NULL
transcription	NULL
factors	NULL
may	NULL
regulate	NULL
the	NULL
transcription	NULL
of	NULL
tissue-specific	NULL
target	NULL
genes	NULL
.	NULL

Acknowledgments-We	NULL
sincerely	NULL
thank	NULL
Angela	NULL
Paulpillai	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

We	NULL
are	NULL
extremely	NULL
grateful	NULL
to	NULL
Steve	NULL
Jackson	NULL
for	NULL
generously	NULL
providing	NULL
the	NULL
anti-Sp1	NULL
antibody	NULL
,	NULL
to	NULL
Richard	NULL
Ric-kles	NULL
for	NULL
the	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
promoter	NULL
DNA	NULL
,	NULL
to	NULL
Ulla	NULL
Hansen	NULL
for	NULL
the	NULL
SV40	NULL
Sp1	NULL
site	NULL
oligonucleotide	NULL
,	NULL
to	NULL
Albert	NULL
Courey	NULL
and	NULL
Robert	NULL
Tjian	NULL
for	NULL
the	NULL
pPacSpl	NULL
expression	NULL
construct	NULL
,	NULL
to	NULL
Pierre	NULL
Cham-bon	NULL
for	NULL
the	NULL
RARa	NULL
expression	NULL
construct	NULL
,	NULL
and	NULL
to	NULL
Catharine	NULL
Kara	NULL
and	NULL
Laurie	NULL
Glimcher	NULL
for	NULL
help	NULL
with	NULL
in	NULL
vivo	NULL
footprinting	NULL
.	NULL

We	NULL
thank	NULL
Joop	NULL
Jansen	NULL
,	NULL
Timothy	NULL
Burn	NULL
,	NULL
and	NULL
Anne	NULL
Satterthwaite	NULL
for	NULL
many	NULL
helpful	NULL
discussions	NULL
and	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
.	NULL

Metcalf	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
339	NULL
,	NULL
27-30	NULL
.	NULL

Peyny	NULL
,	NULL
L.	NULL
,	NULL
Simon	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Robertson	NULL
,	NULL
E.	NULL
,	NULL
Klein	NULL
W.	NULL
H.	NULL
,	NULL
Tsai	NULL
,	NULL
S.-F.	NULL
,	NULL
D'Agati	NULL
,	NULL
V.	NULL
,	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
and	NULL
Constantini	NULL
,	NULL
F.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
349	NULL
,	NULL
257-260	NULL
.	NULL

Martin	NULL
,	NULL
D.	NULL
I.	NULL
K.	NULL
,	NULL
Tsai	NULL
,	NULL
S.-F.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
338	NULL
,	NULL
435-438	NULL
.	NULL

Mignotte	NULL
,	NULL
V.	NULL
,	NULL
Wall	NULL
,	NULL
L.	NULL
,	NULL
de	NULL
Boer	NULL
,	NULL
E.	NULL
,	NULL
Grosveld	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Romeo	NULL
,	NULL
P.-H.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
37-54	NULL
.	NULL

Youssoufian	NULL
,	NULL
H.	NULL
,	NULL
Zon	NULL
,	NULL
L.	NULL
,	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
D'Andrea	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Lodish	NULL
,	NULL
H.	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
3675-3682	NULL
.	NULL

Todd	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Schlossman	NULL
,	NULL
S.	NULL
F.	NULL
(	NULL
1981	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

126	NULL
,	NULL
1435-1442	NULL
.	NULL

Hynes	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
48	NULL
,	NULL
549	NULL
.	NULL

Hynes	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
69	NULL
,	NULL
11-25	NULL
Law	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Gagnon	NULL
,	NULL
J.	NULL
,	NULL
Hildreth	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Wells	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Willis	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
and	NULL
Wong	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
915-919	NULL
10	NULL
.	NULL

Rosmarin	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Weil	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Rosner	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Griffin	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Arnaout	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Blood	NULL
78	NULL
,	NULL
131-136	NULL
11	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Rosmarin	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
and	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
Blood	NULL
79	NULL
,	NULL
865-870	NULL
12	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Scheibe	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Zhang	NULL
,	NULL
D.-E.	NULL
,	NULL
Chen	NULL
,	NULL
H.-M.	NULL
,	NULL
Galson	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Maki	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
in	NULL
press	NULL
13	NULL
.	NULL

Zaret	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Lui	NULL
,	NULL
J.-K.	NULL
,	NULL
and	NULL
Di	NULL
Persio	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
5469-5473	NULL
14	NULL
.	NULL

Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
Biotechniques	NULL
6	NULL
,	NULL
454-457	NULL
15	NULL
.	NULL

Sanger	NULL
,	NULL
F.	NULL
,	NULL
Nicklen	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Coulson	NULL
,	NULL
A.	NULL
R.	NULL
(	NULL
1977	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

74	NULL
,	NULL
5463-5467	NULL
16	NULL
.	NULL

Pahé	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Burn	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
and	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Exp	NULL
.	NULL

Hematol	NULL
.	NULL

19	NULL
,	NULL
1038-1041	NULL
17	NULL
.	NULL

Dingham	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
18	NULL
.	NULL

Darrow	NULL
A.	NULL
L.	NULL
,	NULL
Rickles	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Pecorino	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
and	NULL
Strickland	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
5883-5893	NULL
19	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
Sharp	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
305-318	NULL
20	NULL
.	NULL

Mzgzazém	NULL
,	NULL
12	NULL
M.	NULL
,	NULL
and	NULL
Gilbert	NULL
,	NULL
W.	NULL
(	NULL
1977	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

74	NULL
,	NULL
-56	NULL
21	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ong	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Dyck	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
345	NULL
,	NULL
224-229	NULL
22	NULL
.	NULL

Courey	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
887-898	NULL
23	NULL
.	NULL

Zelent	NULL
,	NULL
A.	NULL
,	NULL
Krust	NULL
,	NULL
A.	NULL
,	NULL
Petkovich	NULL
,	NULL
M.	NULL
,	NULL
Kastner	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
389	NULL
,	NULL
714-717	NULL
24	NULL
.	NULL

Tsai	NULL
,	NULL
S.-F.	NULL
,	NULL
Strauss	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

5	NULL
,	NULL
919-931	NULL
25	NULL
.	NULL

Mueller	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
and	NULL
Wold	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
780-786	NULL
26	NULL
.	NULL

Dynan	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
and	NULL
Tijan	NULL
,	NULL
R.	NULL
(	NULL
1983	NULL
)	NULL
Cell	NULL
35,79-87	NULL
27	NULL
.	NULL

Letovsky	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Dynan	NULL
,	NULL
W.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
2639-2653	NULL
28	NULL
.	NULL

Schaufele	NULL
,	NULL
F.	NULL
,	NULL
West	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
and	NULL
Reudelhuber	NULL
,	NULL
T.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
17189-17196	NULL
29	NULL
.	NULL

Anderson	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
and	NULL
Freytag	NULL
,	NULL
S.	NULL
O	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
1935-1943	NULL
30	NULL
.	NULL

Spggfgoﬁzlgg	NULL
,	NULL
E.	NULL
,	NULL
Giguere	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Grosveld	NULL
,	NULL
F.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
,	NULL
11	NULL
,	NULL
31	NULL
.	NULL

Saffer	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Jackson	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
and	NULL
Annarella	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
2189-2199	NULL
32	NULL
.	NULL

Borellini	NULL
,	NULL
F.	NULL
,	NULL
He	NULL
,	NULL
Y.	NULL
F.	NULL
,	NULL
Aquino	NULL
,	NULL
A.	NULL
,	NULL
Yu	NULL
,	NULL
G.	NULL
,	NULL
Josephs	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
and	NULL
Glazer	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
15850-15854	NULL
33	NULL
.	NULL

Jackson	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
and	NULL
Tijan	NULL
,	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
125-133	NULL
34	NULL
.	NULL

Alemany	NULL
,	NULL
J.	NULL
,	NULL
Klement	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Borras	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
De	NULL
Pablo	NULL
,	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

183	NULL
,	NULL
659-665	NULL
35	NULL
.	NULL

Rigaud	NULL
,	NULL
G.	NULL
,	NULL
Roux	NULL
,	NULL
J.	NULL
,	NULL
Pictet	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Grange	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
67	NULL
,	NULL
977-986	NULL
36	NULL
.	NULL

Shapiro	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Ashmun	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Roberts	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
and	NULL
Look	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
11999-12007	NULL
37	NULL
.	NULL

Hohn	NULL
P.	NULL
A.	NULL
,	NULL
Popescu	NULL
N.	NULL
C.	NULL
,	NULL
Hanson	NULL
R.	NULL
D.	NULL
,	NULL
Salvesen	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
264	NULL
,	NULL
13412-13417	NULL
38	NULL
.	NULL

Fleming	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Gonzalez	NULL
D.	NULL
A.	NULL
,	NULL
Smith	NULL
T.	NULL
F.	NULL
,	NULL
and	NULL
Tenen	NULL
D.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
J	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
480-490	NULL
to	NULL
go	NULL
mi	NULL
&	NULL
gn	NULL
>	NULL
co	NULL
bo	NULL
i	NULL

